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Virulence of Drosophila C virus increased after a host shift and serial passage in
Drosophila hosts
by
Katie A. Johnson
Spring 2020
The outcomes of novel host-pathogen interactions are unpredictable but can result in
epidemics or pandemics. Exploring the initial encounter between a pathogen and a novel
host species can elucidate why some pathogens successfully infect and adapt on a novel
host when others fail. Much of our understanding of host virulence after host shifts was
developed using serial passage experiments (SPEs) in bacteria. Three accepted SPE
generalities have emerged: virulence increases on the novel host, the evolved pathogen
will become less able to infect its native host, and the pathogen experiences convergent
evolution. This study tests the first two generalities using complex hosts (Drosophila sp)
and the highly virulent Drosophila C virus (DCV). The fitness of DCV was utilized as a
proxy for virulence (pathogen’s harm to host) and investigated over 10 serial passages of
the pathogen. The number of eggs, pupae, and adults were measured along with the days
to pupation and to adulthood. We observed significant decreases in fecundity for both
hosts but no significant effects on developmental metrics. The novel host experienced a
significantly larger decrease in survivability than the native host. This decrease in
fecundity and increases in mortality indicate an increase in DCV virulence on the novel
host. Viral load does not explain the increase in virulence. The virus evolved on the
native host was equally virulent to the native host as the ancestral virus, in contrast to
SPE predictions. This study supports the SPE generality of increased virulence in the
novel host even with a physiologically complex host and a highly virulent pathogen.
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CHAPTER ONE
Emerging diseases: a review of influences and mechanisms of a host shift
Introduction
With the world currently in the middle of a pandemic due to the novel
coronavirus, SARS-CoV-2, the need to predict and prevent future host shifts has never
felt more necessary (CLEAVELAND et al. 2001; HOWARD and FLETCHER 2012). Studying
the initial encounter of a pathogen with a novel (new) host can provide insight as to why
some pathogens can successfully evolve to infect a novel host (host shit) when others fail
(HOBERG and BROOKS 2015). Additional knowledge of host shifts can lead to medical
and agricultural benefits such as better vaccine design, prevention of deadly diseases, and
diminish current virulent pathogens (BULL 1994). COVID-19 alone has led to a
detrimental shortage of healthcare supplies, a monumental economic crisis, and
thousands of deaths all within a matter of months. This being due to just one successful
host shift event (CORONAVIRIDAE STUDY 2020). Discussed here are the environmental
and ecological factors that can accelerate host shifts along with the coevolutionary
processes between a pathogen and host. The benefits of the model organism Drosophila
fruit flies and the Drosophila C virus are also covered including methods of analyzing
virulence evolution. This system can be used in the hopes to better understand the critical
interactions that occur at the initial stages of a host shift.
Host Shifts Resulting in Emerging Diseases
Emerging infectious diseases, characterized as previously unknown infections or
those moving into a new environment, have caused widespread illness in humans, plants,
and animals (HOWARD and FLETCHER 2012). A sudden emerging disease currently
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threatening the world is coronavirus disease 2019 (COVID-19) caused by a novel
coronavirus named SARS-CoV-2. Coronaviruses normally have an animal reservoir and
cannot infect humans, however, COVID-19 along with the cases of middle eastern
respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) are proof
the transition is possible. With little to no immunity among the novel host population the
ability to spread worldwide (referred to as a pandemic) is greater. Upon comparison of
the genomic sequences of SARS-CoV-2 between the United States and China, the
similarities suggest the pandemic emerged from a single event. Even though most
pathogens cannot evolve to infect a new host, SARS-CoV-2 is an example of the extreme
effects just one successful host shift can have (CORONAVIRIDAE STUDY 2020). For this
reason, it is important to further analyze how these, and other pathogens, made the shift
along with the processes that can influence these events.
Ecological disturbances from human intervention or natural phenomena have
influenced encounters with novel hosts. These include but are not limited to climate
change, human encroachment, and agricultural practices which can assist the pathogen in
filling new environmental niches (PATZ et al. 2000; HOBERG and BROOKS 2015). New
host-pathogen interactions can result in unpredictable host switching opportunities and
the possibility of widespread infection (epidemics) (HOBERG and BROOKS 2015).
Zoonoses in particular, pathogens transmitted from animal species to humans, have
become an increasing public health concern (WOOLHOUSE and GOWTAGE-SEQUERIA
2005). Besides from the most recent COVID-19 pandemic, the world has faced the
consequences of many other zoonotic events. Hantavirus outbreaks from rodent exposure,
the 2009 H1N1 pandemic, the 2003 epidemic of SARS, the continuing fight against
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human immunodeficiency virus (HIV), and many other pathogens that evolved from
animal hosts have had an impact on human health (HOWARD and FLETCHER 2012).
Host-pathogen evolution is not limited to zoonoses. High mortality rates within
livestock and the agricultural industry have also had a strong socio-economic impact
(CLEAVELAND et al. 2001). For example, bananas and plantains are one of the world’s top
five staple crops but farmers are currently facing the Sigatoka disease complex, the most
deadly banana disease seen worldwide (CHANG et al. 2016). For these reasons, pathogens
with the ability to infect multiple hosts are of importance. Examination of their host shift
mechanisms and viral-pathogen responses can provide key insights (HOWARD and
FLETCHER 2012; CHANG et al. 2016).
Host Shift Mechanisms
Evolutionary biologists have attempted to understand the dynamics of emerging
diseases in order to hypothesize why and how certain pathogens can shift from their
native host to a novel host (CLEAVELAND et al. 2001; ALIZON et al. 2009). A pathogen
faces numerous obstacles when invading a new host. The dynamic process of the host’s
attempt to eradicate the pathogen coupled with the pathogen’s attempt to utilize the host
for survival are discussed here (CHERRY and PERRIMON 2004). There are three main steps
to a host shift: 1) exposure to a novel host 2) infection of the host 3) transmission to other
hosts within the population. Throughout these steps there are multiples factors that can
influence whether or not the pathogen is successful (LICHT 2018).
An initial hurdle a pathogen faces is survival in the new environment. This may
require a novel defense mechanism to fight off enemies not previously encountered. They
may also need to develop other ways to survive in these harsh conditions (HOBERG and
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BROOKS 2015). Additionally, the pathogen is faced with the host’s immune response as it
tries to adhere, invade, and exploit the host’s replication pathway (LINDE et al. 2015).
The innate immune system provides the first line of defense for metazoans and shapes the
subsequent adaptive immune response within vertebrates (SABATIER et al. 2003;
GALIANA-ARNOUX et al. 2006b). For instance, if structures of the pathogen bind to
pattern recognition receptors (PRRs), the host’s immune system will respond by killing
the organism through direct phagocytosis, toxin production, or cytokine release
(SABATIER et al. 2003). The pathogen must be able to evade or suppress the host’s innate
immune response in order to survive and ultimately replicate (CHERRY and PERRIMON
2004; VAN SLUIJS et al. 2017). Lastly, for pathogenic offspring to persist, vital nutrients
must be effectively utilized by exploiting the host (HOBERG and BROOKS 2015).
Pathogens use several methods to bypass these host defenses (ELLISON et al.
2017). Herpes simplex virus 1 (HSV-1), for example, can cause recurrent infection by
targeting certain aspects of the innate and adaptive immune system. The viral
glycoprotein gE of HSV-1 can impair antibody responses by binding to the IgG Fc
domain. Additionally, glycoprotein gC can bind to C3b which plays an important role in
compliment activation along with other molecules to assist HSV-1 in evading the host’s
immunity (LUBINSKI et al. 1999). Since the advances of molecular techniques, specific
genetic adaptations may be identifiable, however, individual host-pathogen interactions
produce variable outcomes. This variability makes them not only difficult to predict but
also suggests diverse environmental and genetic factors play a key role within pathogenhost coevolution (DUNEAU et al. 2017; VERTACNIK and LINNEN 2017).
Ecological Pressures on Host Shifts
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The risk of an emerging disease can be influenced by environmental pressures
placed on a pathogen-host interaction (CLEAVELAND et al. 2001; DESJARDINS et al.
2017). Ecological disturbances, both natural and human caused, can alter the overall
balance of the community (PATZ et al. 2000; MORLEY et al. 2015). Significant examples
of human drivers that can lead to an imbalance include encroachment on wildlife,
urbanization, deforestation, and altered land use (PATZ et al. 2000). Humans can
influence the density of the host, the pathogen, or the vector which can in return increase
interactions or even encourage novel associations (ROGALSKI et al. 2017). A sharp
increase in the cases of arenavirus in humans was a historical demonstration of the health
consequences caused by agricultural practices. The increase in agricultural crops
influenced an increase in rodent populations. This amplified the contact between humans
and rodents which ultimately supported an increase in transmission of the zoonotic
disease (DOMINGO and HOLLAND 1997).
The more recent ease of travel, especially by air, has caused population mixing
(introduction of host with parasite). This mixing can impact the pathogenicity of the
parasite and encourage rapid transmission to new hosts (HOWARD and FLETCHER 2012;
GOMEZ et al. 2015). A noteworthy example from 2003 was the introduction of SARS to
new areas by air travel. It took just 1 week to introduce SARS to 17 additional countries
(HOWARD and FLETCHER 2012). At the start of COVID-19, restrictions on travel was a
vital action taken in hopes to decrease the potential of a pandemic.
We are also currently living in a time of accelerating climate warming. Climate
change in both the sporadic and gradual context can force community fluctuations by
straining native species’ growth. The fluctuation can simultaneously allow novel hosts to
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fill the void (PATZ et al. 2000). Scientists are coming to the realization a better
understanding of host shifts can be reached through the study of historical events coupled
with continual monitoring of the ecological impacts. While human disturbance and
natural phenomenon will continue to influence pathogen-host interactions, putting more
effective air travel and physical perturbation restrictions in place can help prevent future
incidences (HOWARD and FLETCHER 2012; HOBERG and BROOKS 2015).
Genetic Pressures on Host Shifts
On a molecular level, an evolutionary arm’s race between the host and pathogen
occurs. This race can drive adaptations in the pathogen which can alter its fitness
(CLEAVELAND et al. 2001; LONGDON et al. 2018). The likelihood of a successful shift
first relies on exposure of the pathogen to the novel host. The second factor includes the
underlying genetic compatibility. Recognizing their impact can help in the predictions of
host jumps (PARKER and GILBERT 2004; CHANG et al. 2016). Phylogeny studies have
shown an increased tendency of a host shift to occur if the species are closely related,
referring to the process as ‘ecological fitting via resource tracking’ (LONGDON et al.
2015; LICHT 2018; LONGDON et al. 2018). Closely related species have shown parallel
genetic changes, referred to as convergent evolution. This evolution suggests a pathogen
that has successfully adapted to a host, is now better adapted to other closely related hosts
(CHANG et al. 2016; LONGDON et al. 2018).
While some species may be pre-adapted to evolve to infect a new host, numerous
experimental findings support the idea that a majority of genetic variation takes place
during the host shift process (LONGDON et al. 2018). The ability of a pathogen to adjust to
a novel host that contains resources not previously encountered is thought to rely on the
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extent of genetic plasticity (LICHT 2018). The plasticity involves the ability to increase
fitness on the novel host by producing an adapted phenotype from a genotype previously
hidden by natural selection. RNA viruses, in particular, can have large genetic diversity.
They have higher rates of mutation due to the proofreading inability of RNA polymerase.
This means each mistake the enzyme makes goes unfixed. The mutations have benefited
the pathogen’s ability to establish infection in a new host. For instance, the avian
influenza virus accumulated mutations which allowed for better binding and RNA
polymerase activity within mammalian cells (LICHT 2018).
RNA viruses are especially prone to becoming an emerging disease due to their
high genetic plasticity and short replication times (DOMINGO and HOLLAND 1997;
CLEAVELAND et al. 2001; DUFFY et al. 2008; HOWARD and FLETCHER 2012). They
produce genetic variation by forming mutant swarms of RNA viruses known as
quasispecies. The quasispecies can be produced through mutations, genome segment
sorting, and recombination. The variation equips them with a higher probability of filling
new niches (DOMINGO and HOLLAND 1997; DRAKE and HOLLAND 1999; CLEAVELAND et
al. 2001). Complex hosts, such as humans, evolve at a much slower rate than RNA virus
pathogens. For this reason it seems the host would not be able to keep up with the
pathogen’s evolution allowing the viral infection to go uncontrolled, however, this is not
always the case (SHIN and MACCARTHY 2016). Humans contain superior defense
mechanisms suggesting host shifts are multifaceted and the study of genetic factors alone
does not have the ability to predict pathogen expansion (SHIN and MACCARTHY 2016;
VERTACNIK and LINNEN 2017).
Evolution of Virulence
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While evolutionary biologists have studied parasite-host co-evolution for decades,
the ability to predict whether a host shift will result in a major outbreak versus going
relatively unnoticed has proven a difficult task (LEVIN 1996; BRUSINI et al. 2013). When
studying the shift of Ebola virus, HIV, and SARS virus, an increase in pathogen virulence
(the pathogen’s degree of harm to host) was noted following each host shift (ALIZON et
al. 2009). Virulence can sometimes be a consequence of pathogen replication or from
infecting tissue that has no adaptation value to the pathogen. Some pathogens that are
found to be largely asymptomatic in the native host, but can be deadly to the novel host
(LONGDON et al. 2015). For instance, the virus SARS-CoV naturally demonstrates little
to no signs of infection in bats, its reservoir host, but the virus can cause severe
respiratory symptoms in humans (WATANABE et al. 2010). These findings have lead
scientists to believe there is a strong correlation between virulence evolution and host
shift severity, but little is still known (LONGDON et al. 2015).
There have been several hypotheses proposed surrounding virulence evolution.
Logic initially supported the idea that a fully evolved pathogen would not want to kill its
host too quickly. If the host dies immediately, the pathogen may not be able to fully
exploit the host’s resources or successfully transfer to a new host (REGOES et al. 2000).
The avirulence hypothesis was born from this idea, specifically suggesting a parasite
evolves towards an end goal of harmless co-existence (LEVIN 1996; JANSEN et al. 2015).
The avirulence hypothesis became so accepted that many referred to it as ‘conventional
wisdom’ (ALIZON et al. 2009). With only a few systems to support these claims, and the
fact that not all evolved pathogens have been shown to become less virulent over time, a
more recent hypothesis arose (MAY and ANDERSON 1983).
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After a period referred to as ‘enlightenment’ in 1980, a new idea surrounding
virulence evolution was proposed. It was developed in 1982 and 1983 by R. M. May &
R. M. Anderson and Paul W. Ewald, respectively, known as the trade-off hypothesis
(EWALD 1983; MAY and ANDERSON 1983; ALIZON et al. 2009). The hypothesis
suggested a series of trade-offs occur between the pathogen’s level of virulence and
transmission rate (EWALD 1983; ALIZON et al. 2009). For instance, with high levels of
virulence a positive outcome of rapid and vigorous host exploitation occurs, but could
lead to host death before the pathogen can successfully spread within the host population
(FRANK 1996; ALIZON et al. 2009). One of the most recognized early models supporting
the claim of host-parasite coevolution was the use of myxoma virus to control European
rabbit populations. A highly virulent strain of myxoma virus was released, killing most of
the rabbit population quickly. The highly virulent strains were at a disadvantage because
they killed the host too quickly, but the strains that were too attenuated did not produce
enough lesions which limited the virus’ spread to the rest of the population. The virus that
was later recovered from the rabbit population had a lower virulence and transmission
rate than the starting myxoma virus but was still significantly more virulent than the
viruses attenuated within the laboratory setting. This experiment supported the
enlightenment theory that natural selection could select and still maintain virulent strains
instead of just evolving to become more avirulent. It provided evidence of a trade-off
between transmission and virulence (LEVIN 1996).
As more examples of coevolution were reviewed, there was a realization that
while the trade-off hypothesis could teach us important information about host shifts, it
was still too simplistic to fully explain virulence evolution (ALIZON et al. 2009;
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LONGDON et al. 2015). The variability of virulence between different pathogens
suggested parasite evolution is influenced by more than just transmission rates and
virulence levels (MACKINNON and READ 2004). In 1996 Steven A. Frank proposed
additional trade-offs that may also greatly impact the coevolution. The trade-offs
included competition for the same resources (tragedy of the commons) and within-host
competition (FRANK 1996). Additional implications were made for the diversity of the
host population (heterogenous vs homogenous) and immunity (resistance vs tolerance
mechanisms) (REGOES et al. 2000; MACKINNON and READ 2004; BEST et al. 2014). The
original hypotheses behind the evolution of virulence relied heavily on theoretical
mapping and examination of ‘natural systems.’ While virulence has been widely
recognized as an important component of host shifts, the mechanisms behind this
evolution is still relatively unknown (ALIZON et al. 2009; LONGDON et al. 2015).
However, the knowledge of genetic and ecological mechanisms involved with virulence
evolution has since progressed through the use of serial passaging experiments and
molecular advances (EBERT 1998; LONGDON et al. 2015).
Serial Passaging Experimentation
Serial passaging experiments (SPEs) have been used to make vaccines through
pathogen attenuation. SPEs have also become a powerful tool for evolutionary biologists.
(EBERT 1998). During a SPE the pathogen is transferred from one host to the next while
observing the evolution characteristics over time (EBERT 1998). SPEs can allow for the
adaptation to a new host within a matter of days. The experiment can also allow for
control of certain aspects within the environment, transmission mode, viral load, and
genetic diversity, amongst other factors (EBERT 1998). Having the ability to control
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certain aspects of the host-pathogen interaction can allow researchers to come to more
definitive conclusions (ALIZON et al. 2009). Many changes in virulence have attributed to
mutations or other recombinant events during the passaging process. For this reason,
SPEs that can be coupled with gene expression analysis technology have provided
important insight on the molecular mechanisms behind host shifts (LINDE et al. 2015).
New technology has even allowed for these genetic adaptations to be analyzed in real
time (VANGUILDER et al. 2008; LINDE et al. 2015).
The trade-off hypothesis has been under critical review since it was originally
proposed. It utilized the observation approach (collecting specimens from nature and
analyzing trait pairs) along with the comparative approach (larger pooling of specimens)
(ALIZON et al. 2009). Since utilization of the experimental approach the most compelling
data on changes associated with coevolution has been discovered (ALIZON et al. 2009;
LONGDON et al. 2015). For instance, rapid shifts in pathogen virulence have been
documented in H5N2 avian influenza virus after just one serial passage in mice. This
experiment showed alterations of two amino acids were responsible for the increased
pathogenicity (NAM et al. 2017). Serial passaging of the bacteria Corynebacterium
pseudotuberculosis similarly demonstrated changes in gene expression allowing the
bacterium to evade the novel host’s immune system and increasing virulence (SILVA et
al. 2017). While altered resistance and virulence over time have been a paralleled finding
in more recent coevolution SPEs, a full understanding of the role of viral loads, the
diversity of host and parasite, the specificity of the parasite, etc., play on genetic
adaptations has not been obtained (DENNEHY et al. 2006; LITTLE et al. 2006; BETTS et al.
2018; BONNEAUD et al. 2018).
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A key component of emerging and re-emerging diseases relies on successful
transmission to new hosts, making it a focus for SPEs (VAN DEN BOSCH et al. 2010;
ANTONOVICS et al. 2017). There are two modes of transmission: vertical and horizontal
(ANTONOVICS et al. 2017). Vertical transmission involves a transfer of the pathogen from
parent to offspring via reproduction, while horizontal transmission includes transfer of
infection from the environment (direct or indirect) (VAN DEN BOSCH et al. 2010; LE
CLEC'H et al. 2017). A trade-off between the two modes of pathogen transmission are
believed to occur when infecting and adapting to a new host (VAN DEN BOSCH et al. 2010;
LONGDON et al. 2011b). Ecological theory predicts vertical transmission alone will result
in lower virulence while horizontal transmission needs to maintain a higher level of
virulence (LIPSITCH et al. 1995; LIPSITCH et al. 1996; LE CLEC'H et al. 2017). This theory
supports the idea that horizontal transmission can cause rapid increases in virulence. The
unregulated effects of horizontal transmission utilizing Wolbachia, an endosymbiont
bacteria, with a native host that is normally unaffected by Wolbachia is an example of
this theory (LE CLEC'H et al. 2017). After a few serial passages of Wolbachia the bacteria
evolved from unharmful to a true pathogen to the native host. Similar horizontal
transmission findings were discovered using the intracellular bacterium Coxiella burnetii
(LE CLEC'H et al. 2017).
Previous research within the Matos laboratory has focused on the Drosophila fruit
fly model and Sigma virus, a vertically transmitted and mildly virulent RNA virus, to
study the early stages of a host shift ((HENDRIX 2018; MONSANTO-HEARNE and JOHNSON
2018). In that work, the Sigma virus was passaged naturally (vertically) within the fly
populations for 20 fly generations. Although virulence did increase on the novel host (as
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predicted), the virus did not evolve. It is possible that the vertically transmitted nature of
the Sigma virus produced a natural bottleneck that selected for a particular viral genotype
(BRUSINI et al. 2013). Further work in the Matos lab suggested that host immunity may
also play a key role in how the novel host responds (HENDRIX 2018). Therefore, the low
virulence of Sigma virus mixed with the known host response and the vertical nature
(transovarial) of the virus may have confounded the results. Future studies could benefit
from investigation of the pathogen evolution following a host shift when the pathogen is
highly virulent and horizontally transmitted.
Drosophila as a Model Host
Model systems have long been used as a simple and effective way of studying
underlying evolutionary mechanisms with the ability to apply findings to more complex
models (VAN SLUIJS et al. 2017). The Drosophila fruit fly is an extensively studied
complex multicellular organism used as a model system for over a century (ADAMS et al.
2000; BIER et al. 2018). Many of the antiviral defense responses have been conserved
between Drosophila and invertebrates making them a useful model for evolutionary
studies (OSBORNE et al. 2009). Since Drosophila was chosen as a model organism in
1990 for the Human Genome Project, it has become an important tool for genetic
research also (ADAMS et al. 2000; CLARK et al. 2007). The genetic components of
Drosophila have been well-characterized allowing much of their development, metabolic
processes, and innate immune system responses to be applied to biological processes in
vertebrates (SABATIER et al. 2003; PONTON et al. 2011). Tools such as FlyBase,
GenBank, FlyAtlas, and protein-interaction maps provide not only the Drosophila
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genomic sequence but also the ability to parallel human genetic diseases (GIOT et al.
2003; CHINTAPALLI et al. 2007; CLARK et al. 2007; PONTON et al. 2011).
Additional advantages of Drosophila include the ability to easily collect wild
populations. These species can be used for laboratory experiments, specifically viral
pathogenicity research due to their ability to be infected with over 30 viruses in nature
(VAN SLUIJS et al. 2017). Drosophila melanogaster can be infected with human
pathogens including West Nile virus and Sindbis virus (VAN SLUIJS et al. 2017). Lastly,
the organism has a relatively small genome (~180 megabases) making molecular
techniques less costly than mice or other complex models (ADAMS et al. 2000).
Horizontal transmission of Drosophila C virus using Drosophila melanogaster as the
native host and Drosophila mauritiana as the novel host can provide genetic and
virulence evolution information that can be applied to other host-pathogen systems.
Drosophila C Virus as a Model Pathogen
Drosophila C virus (DCV) is a nonenveloped, positive-sense, single-stranded
RNA virus. It is a member of the Dicistroviridae family originally isolated in the French
Charolles strain of Drosophila melanogaster in the 1970s (JOUSSET et al. 1977;
SABATIER et al. 2003). It is one of the most highly studied Drosophila viruses making it a
good model pathogen (GALIANA-ARNOUX et al. 2006b; OSBORNE et al. 2009). DCV is
endemic among Drosophila melanogaster meaning it has coevolved with this species.
There are numerous species of Drosophila DCV is not normally found to infect in nature
but can cause infection in a laboratory setting such as Drosophila mauritiana. For this
reason, DCV can be used for host shift experiments using closely related species. DCV is
an even more suitable tool for evolution research due to the high mutation rates of RNA
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viruses which results in high genetic diversity (DUFFY et al. 2008). It also has not been
found to shift to humans, making it safe to work with in the laboratory setting (LONGDON
et al. 2015).
The pathogen is naturally spread by horizontal transmission through ingestion or
close contact. Microinjection can be utilized in order to achieve artificial infection. The
injection process allows for horizontal transmission with no significant effects on the
species (CHERRY and PERRIMON 2004). It is also highly virulent even to the native host
causing infected flies to die within 4-6 days (SABATIER et al. 2003; OSBORNE et al. 2009).
Vertebrate picornaviruses closely resemble DCV so studying the interaction of
Drosophila mauritiana and melanogaster with DCV can uncover infectious mechanisms
relative to human pathogens such as poliovirus and foot-and-mouth disease (CHERRY and
PERRIMON 2004). For example, studies have indicated a subset of genes that are induced
by DCV. These genes are regulated by the Jak-STAT pathway which was initially found
in mammals for interferon signaling (part of the innate immune response). The results
suggest some mechanisms for responses to infection are evolutionarily conserved
(GALIANA-ARNOUX et al. 2006a).
Changes in Fecundity/Fitness as an Indication of Host Response
While Drosophila cannot mount an adaptive immune response, they do have an
innate immune system that is like that of other complex organisms. For this reason, hostpathogen interactions using Drosophila have been well studied (Galiana-Arnoux et al.,
2006). Research has indicated Drosophila species have the ability to fight off some
infections enough to survive, but the deployment of the innate immune response may
impose a cost on components of host fitness (AHMED et al. 2002). The immune response
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cannot be effectively deployed while maintaining all fitness aspects. This means fighting
off the infection can come as an indirect cost to fitness (MORET and SCHMID-HEMPEL
2000). The cost of survival can result in decreases in fecundity believed to be a coping
mechanism. During a SPE the changes in fitness through measures such as fecundity and
mortality can then be correlated with changes in pathogen virulence. In theory, the more
virulent the pathogen, the lower the host fecundity. This proxy for virulence is an easier,
more visual method of measuring virulence evolution which can then be paired with such
things as genome sequencing and metabolomics (MCKEAN et al. 2008).
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CHAPTER TWO
Drosophila C virus virulence increased after a host shift and serial passage in Drosophila
hosts
Introduction
Pathogen host-shifts can dramatically affect the world: this was plainly evident
with the host shift of SARS-CoV-2 into humans in 2019. The novel coronavirus disease2019 (COVID-19) quickly reached pandemic status; filling hospitals with patients,
causing businesses to close, and influencing unprecedented lifestyle changes around the
world. While COVID-19 has been the most disruptive host-shift event of the last 100
years, it is not the only novel pathogen we’ve seen in that time. Among recent examples
are severe acute respiratory syndrome (SARS, 2002), middle eastern respiratory
syndrome (MERS, 2012), and human immunodeficiency virus (HIV, 1981) (SHARP and
HAHN 2011; CORONAVIRIDAE STUDY 2020). Each of these pathogens was able to shift
from an animal reservoir to a human (WOOLHOUSE and GOWTAGE-SEQUERIA 2005).
These shifts into humans are known as zoonoses. Luckily most pathogens cannot
successfully effect a zoonotic event because these are low odds events with numerous
factors influencing the process (LICHT 2018).
There are three main steps to a host shift by a pathogen: 1) pathogen exposure to a
novel host species, 2) successful infection of the novel host, and 3) pathogen transmission
to other hosts within the population. The likelihood of a successful shift to a novel host
first relies on exposure of the pathogen to the novel host. An initial hurdle a pathogen
faces is survival in the new environment (PARKER and GILBERT 2004). Additionally, the
pathogen is faced with the host’s immune response as it tries to adhere, invade, and
exploit the host’s replication pathway (LINDE et al. 2015). The pathogen must evade or
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suppress the host’s response in order to survive and replicate within the host (CHERRY
and PERRIMON 2004; VAN SLUIJS et al. 2017). Once vital nutrients are effectively
obtained by exploiting the host, transmission to the next host must be completed
(HOBERG and BROOKS 2015). If the exploitation occurs too rapidly the host dies before
transmission can occur (FRANK 1996). These obstacles have strong selective pressures
which can ultimately lead to rapid pathogen adaptation (PARKER and GILBERT 2004).
Phylogeny studies indicate an increased likelihood of a host shift to occur if the
native and novel host species are closely related, referring to the process as ‘ecological
fitting via resource tracking’ (LONGDON et al. 2015; LICHT 2018; LONGDON et al. 2018).
This type of ecological fitting is possible when the pathogen, upon introduction to the
novel host, is readily able to cause infection. If the novel host is genetically comparable
to the native host, the pathogen has little to no new obstacles to overcome in order to shift
to the novel host (LICHT 2018). Closely related species have shown parallel genetic
changes, referred to as convergent evolution, which suggests there are key changes to
molecular pathways in order to increase virulence (CHANG et al. 2016; LONGDON et al.
2018). These results suggest an understanding of both the ecological and genetic
influences on host shifts are necessary to better predict and prevent future occurrences.
While studying host shifts, a common change in virulence (pathogen’s harm to host) has
been noted. There appears to be an increase in virulence immediately following a shift to
a novel host. These findings lead scientists to believe there is a strong correlation
between virulence evolution and host shift severity (ALIZON et al. 2009). Studying host
shifts and virulence evolution, is commonly performed using serial passaging
experimentation (SPEs) where the pathogen is transmitted from one host to the next.
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Three long-held generalities emerged from classic SPE studies: 1) the pathogen will
increase in virulence on the novel host, 2) the evolved pathogen will be less able to infect
the native host, 3) and the pathogen will experience convergent evolution (BULL 1994;
EBERT 1998). Many of these SPE studies were completed using bacterial hosts and phage
pathogens. This experimental approach can give fast results and allows for many
passages, but bacteria may not show the same response to a novel pathogen that might be
exhibited by a more complex host. Additionally, the pathogens used tend to have low
virulence on the native host (BULL 1994). In the current study, we investigate pathogen
evolution following a host shift by a highly virulent pathogen (Drosophila C virus) and a
complex host (Drosophila sp.).
Drosophila sp. are ideal hosts for SPE studies for several reasons. They are
inexpensive to house and they can be kept in large numbers in an incubator. This
provides the ability of larger sample sizes. Drosophila contain an innate immune
response which is physiologically similar to the human response. The antiviral defense
responses between Drosophila and vertebrates are particularly similar (ADAMS et al.
2000; BIER et al. 2018). Findings from Drosophila have therefore been utilized to gain a
better understanding of basic biological functions of mammals (PONTON et al. 2011).
Drosophila can also be artificially infected with pathogens via microinjection allowing
for controlled horizontal transmission.
Drosophila C virus, a single-stranded RNA virus, is highly virulent and first
discovered in D. melanogaster, killing the flies within 4-6 days. DCV can also infect
others species of Drosophila within a laboratory setting via artificial infection (GALIANAARNOUX et al. 2006b; OSBORNE et al. 2009). The RNA virus is made up of roughly 9,264
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nucleotides with 2 non-overlapping open reading frames: ORF1 and ORF2. ORF1
encodes for a polypeptide involved in replication while ORF2 encodes the second
polypeptide containing 4 structural proteins that form the capsid. DCV produces genetic
variation by forming mutant swarms known as quasispecies, seen especially in RNA
viruses. The short generation time, high pathogen virulence, and ability for the RNA
virus to evolve quickly makes this an ideal system to study virulence evolution
(DOMINGO and HOLLAND 1997; DRAKE and HOLLAND 1999; CLEAVELAND et al. 2001).
The genetic and fitness evolution was compared between the native and novel
host to identify any differential responses to DCV at the initial stages of a host shift. By
utilizing horizontal transmission, the more virulent strains of DCV may be represented in
the population when compared to vertical transmission (LIPSITCH et al. 1996). D.
melanogaster (Emel) was utilized as our native host and D. mauritiana (Maur) as our
novel host. This work included 10 passages (denovo infections of naïve native and novel
hosts with virions extracted from flies infected in the previous passage) in order to test
the three generalities. The viral fitness was examined (RT-qPCR) along with the host
fitness (proxy for virulence) at passages 1, 5, and 10. The fecundity of both host species
significantly decreased from passage 1 to 10, but the developmental times remained
unchanged. This suggests DCV virulence increased but results from RT-qPCR analysis
did not show a change in the viral titer for either host. The Maur-evolved DCV was
injected into naïve native hosts to test the hypothesis that the novel evolved virus would
be less able to infect the native host. The native host still showed significant decreases in
fecundity, but developmental and survivability times did not change. Lastly, the viral
quasispecies was to be sequenced at the beginning (un-evolved) and after 10 passages on
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the native and novel hosts. The sequencing was not completed for the evolved virus due
to the research restrictions put in place as a response to COVID-19. For this reason, the
hypothesis of convergent evolution could not be tested.
MATERIALS AND METHODS
Fly Lines
The two Drosophila fly lines for this experiment were received from the
University of California San Diego Drosophila Stock Center. D. melanogaster was used
as the native host due to DCV naturally occurring in the fly line and D. mauritiana as the
novel host where DCV is not found in nature. Both the native and novel host were highly
inbred contributing to little genetic diversity within each species (HENDRIX 2018).
Fly Rearing
Flies were reared in an incubator kept at a relative humidity of 70% and
temperature of 24°C. The incubator was set to a photoperiod of 16:8 light:dark with
periods mimicking external light and dark times to minimize fly disturbance during
opening of the incubator. The fly colonies were maintained using standard narrow fly
vials. Each plastic Genesee Scientific vial (www.geneseesci.com; CAT #32-120) was
filled with 7 ml of Jazz-Mix (www.fishersci.com) cornmeal growth medium (prepared as
per manufacturer’s recommendations). Once the vials were cooled, a few grains of
baker’s yeast and 1/8 of a KimWipe® was inserted into the edge of the cornmeal growth
medium. Each vial was plugged with a cotton ball. Fly lines were maintained by
combining 5 male and 5 female flies per vial and leaving them to oviposit for 7 days.
Subsequently, the flies were cleared from vials. New oviposition vials were setup every
21 days.
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DCV Inoculum and Artificial Infection
DCV inoculum was donated by Dr. Tanya Miura from the Department of
Biological Sciences at the University of Idaho. The inoculum received was prepared in
cell culture using D. melanogaster cells. The inoculum was received at a concentration of
2 x 106 Median Tissue Culture Infectious Dose (TCID50) units/mL. The inoculum was
split into 200µl aliquots and stored at -80°C.
Horizontal transmission was achieved by artificial injection. A 3.5” glass needle
blank (www.drummondsci.com; CAS #3-000-203-G/X) was pulled by a Kopf Model 720
vertical needle puller then attached to a Nanoject II Auto-Nanoliter injector
(www.drummondsci.com). The needle was filled with physiological grade mineral oil
(www.sigma-aldrich.com; CAS #8042-47-5) attached to the injector, then back-filled
with either DCV inoculum or Schneider’s medium as the negative control.
The first serial passage included injection of both the native and novel host with
the DCV inoculum provided by Dr. Miura. A total of 240 female flies per host species
were injected. An additional 5 flies per host were injected and frozen immediately at 80C. These 5 flies were used later as the target and control calibration samples during
analysis (Day 0 flies) for viral fitness analysis. These flies were 3 to 5 days old at the
time of infection. For the injection procedure, the females were anesthetized on a CO2
flow bed and injected with 59.8nl of DCV per fly. The injection site was within the third
dorsal tergite. Additionally, 24 flies from each host species were injected with 59.8nl of
Schneider’s medium as the negative control. After injection, each fly was placed in a vial
with 7ml of cornmeal growth media. Each female was provided with a male from her
respective species. The vials were capped with a cotton ball and placed in the incubator.
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The 240 flies were divided into 3 viral lineages (72 flies per lineage) and maintained as
replicates throughout the entirety of the serial passage experiment (10 passages in total).
Mortality was monitored until the LT50 point, the time by which 50% of the
DCV-injected flies died, was reached for each lineage or until 10 days, whichever came
first. Once the LT50 was reached, all remaining live flies were collected and immediately
frozen at -80C separately for each lineage. The 10 collected live flies from each viral
lineage (3 lineages per host) at the LT50 point was then used to generate inocula for each
lineage (3 experimental replicates) and used to start the next passage (in this instance
passage 1 to passage 2) (Figure 1). The inoculum was produced by homogenizing the 10
collected flies in Schneider’s medium followed by centrifugation (Appendix IV). The
supernatant (containing DCV) was injected into naïve native and novel female hosts for
each viral lineage to start passage 2. A total of 24 naïve female flies from each host were
injected with freshly thawed Schneider’s medium at each passage used as the negative
control. This process was repeated for serial passages 2 through 10 maintaining the
lineage replicates for each host species.
Each of the fitness passages (1, 5, and 10) had a total of 72 naïve female flies per
lineage injected with the unique DCV inoculum per fitness passage (2 species x 3
lineages x 72 flies = 432 flies injected per fitness passage). After the injection an
uninfected male was added to the vial. All other passages followed the same procedure of
injection and infected fly processing to make the new inoculum. The number of female
flies injected with the DCV inoculums was also reduced as we did not need so many
without the fitness analysis. The number of flies injected with the negative control
remained the same at 24 female flies per host species. The number of female flies
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injected with the each DCV inoculum was reduced to 48 flies per lineage for a total of
168 flies injected per host species. In total, 3,792 flies were injected over the ten
passages, 480 with Schneider’s medium and 3,312 with the unique DCV inoculums.
Fly Fitness as Virulence Proxy
Fly fitness by means of impacts on egg production and development success
(harm to host) were utilized as a proxy for DCV virulence at serial passages 1, 5, and 10.
The number of eggs oviposited (fecundity) and number of adults emerging from those
eggs in each respective vial were counted. Hatchability (proportion of eggs that hatched)
was also determined. To determine fecundity and hatchability, immediately after
injection with DCV or negative control medium, each fly was placed individually in a
vial prepared as above. However, the food in the vial was tinted green (McCormick Food
dye) to improve egg visibility. The flies were allowed to oviposit for 24 hours and the
number of eggs on the green tinted media were then counted. After another 24 hour
period, the number of unhatched eggs were counted to calculate hatchability (Figure 3).
Subsequently, the number of days until the first pupa was observed and days until
the first adult emerged were recorded. The number of total pupae were counted on day 10
post infection for each vial. The number of males and females, and total adults were
counted day 21 post infection. This allowed enough time for completion of the normal
Drosophila life cycle, but not enough time for the offspring’s next generation to emerge
as adults within the same vial. In addition to fecundity and development, the number of
deceased flies were monitored every 24 hours post injection for 10 days or until the LT50
point was reached. Shifts in the LT50 were inversely related to shifts in virulence.
Evolved novel virus on native host
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A separate passage was performed to test the generality that the evolved novel
virus would be less able to infect the native host. The same methods of artificial injection
were utilized as with serial passages 1 through 10. The main difference being only the
DCV inoculums from the novel host (D. mauritiana) were used for injection into the
native host (D. melanogaster). The inoculums were collected from the 3 lineages of the
novel host at the end of passage 10 (Appendix IV). Once the native host females were 3-5
days old, 72 female flies were injected with 59.8nL of the evolved novel host DCV
inoculum for each lineage for a total of 216 DCV infected flies. An additional 24 female
native host flies were injected with the Schneider’s medium control. The LT50 point was
monitored every 12-24 hours immediately after injection and either until 10 days or the
LT50 was reached. Fly fitness by means of egg production, development to pupae,
number of pupae, days to adult, and number of adults were also collected in parallel to
the information gathered during the fitness passages 1, 5, and 10.
Viral Fitness
DCV fitness was measured by viral genome reverse transcription followed by
quantitative polymerase chain reaction (RT-qPCR) which demonstrated the relative
amount of viral RNA present at passages 1, 5, and 10 (Figure 2). Once the LT50 points
were reached, 20 surviving flies were collected from each infected lineage and frozen at 80°C. RNA isolation with TRIzol® reagent was then performed on each fly individually
(20 replicates x 6 lineages x 3 passages = 360 samples total). Each fly was homogenized
using a 1.5mL clean reusable Kimble® 749515-0000 Kontes® Pellet Pestles® Tissue
Grinder in TRIzol® reagent. Once only wings and exoskeleton remained, the sample was
mixed briefly by vortexing. Phase separation occurred after the addition of chloroform.
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The upper aqueous phase was transferred to a fresh tube and isopropyl alcohol added.
The sample was vortexed and centrifuged forming a white pellet. After washing the RNA
pellet with ethanol, it was dissolved in DEPC-treated RNase-free water with RNase
inhibitor (Appendix I). The RNA purity and concentration were determined using a
NanoDrop™ Light spectrophotometer (www.thermofisher.com).
Isolated RNA was reverse transcribed (RT) using the Promega GoScript™
Reverse Transcription System (www.promega.com; CAT #A5000). The isolated RNA
was combined with random hexamer primers and nuclease-free water for a final volume
of 5µl. The combination was heated in a 70°C heat block, chilled on ice, then centrifuged.
In a separate tube, GoScript™ 5X reaction buffer, 2mM MgCl2, PCR nucleotide mix,
recombination RNasin® ribonuclease inhibitor, GoScript™ reverse transcriptase, and
nuclease-free water was combined for a final volume of 15µl. The 15µl reverse
transcription mix was combined with the 5µl primer and RNA mix. Annealing and
extending were completed followed by inactivation of the reverse transcriptase in a heat
block (Appendix II).
RT was followed by qPCR using Bio-Rad SsoAdvanced Universal SYBR®
Green Supermix (www.bio-rad.com; CAT #1725271). Previously published primers
(Forward: 5’-GACACTGCCTTTGATTAG-3’ and Reverse: 5’CCCTCTGGGAACTAAATG-3’) for DCV were used to quantify the viral RNA load
(LONGDON et al. 2015). To ensure genomic RNA was amplified rather than messenger
RNA, the DCV primer spanned the intergenic region of the viral genome (LONGDON et
al. 2015). The Drosophila housekeeping gene RpL32 (Ribosomal protein L32),
established by Longdon, et al. 2011, was used as a reference gene for the RT-qPCR
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(Forward: 5’-TGCTAAGCTGTCGCACAAATGG-3’ and Reverse: 5’TGCGCTTGTTCGATCCGTAAC-3’). Each sample was run separately with DCV
primers and RpL32 primers in three technical replicates for each (360 samples x 3
technical replicates = 1,080 for each primer set). qPCR was performed on a Bio-Rad CFX
Connect™ Real-Time System for 2 minutes at 95°C then 40 cycles at 94°C for 10
seconds, 55°C for 30 seconds, and 72°C for 30 seconds (Appendix III). In order to
estimate the RT-qPCR viral load values, the cycle threshold (Ct) values, the number of
cycles for the flourescence to exceed the background, were determined. In order to
estimate the relative quantifiation of the DCV viral load for each sample a housekeeping
gene (RpL32) was used. This reference gene controlled for differences in sample quantity
and gave a fold change of the DCV gene relative to the reference gene. All samples were
also placed on the plates in a randomized order to account for plate effect. Comparing the
Ct values of the housekeeping gene to the DCV gene for each sample provided a way to
track changing viral titers from passage 1 to 10 (LONGDON et al. 2011a).
Convergent Evolution Test
Genomic analysis of DCV from the initial inoculum and from DCV isolated after
serial passage 10 was to be compared to determine whether DCV evolved, specifically by
converging on a common genotype (Figure 2). Passaged viral RNA was a collection of
50 surviving flies at the LT50 point from each viral lineage per host species (100 flies
injected x 6 viral lineages). The 100 female flies were injected with 59.8nl of the DCV
inocula from passage 10 for each host lineage. RNA from unpassaged (ancestral
inoculum) and passaged virions was isolated using TRIzol® RNA purification (Appendix
I). The cDNA product from each viral lineage (3 viral lineages per fly line = 6 samples)
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along with the initial DCV inoculum was to be sequenced with a MinION device by
Oxford Nanopore Sequencing Technologies. The MinION Direct cDNA Sequencing Kit
SQK-DCS109 and MinION flow cell FLO-MIN106 (www.nanoporetech.com) were to be
used to identify and quantify the full length, intact DCV genome (Appendix V).
Additionally, given that PCR was not used, each molecule sequenced would have
corresponded to genetic material from a unique virion genome, thus enabling the genetics
of the quasispecies population to be determined.
Custom primers were used for sequencing the genomic RNA without
amplification and without using the Nanopore barcoding kit while successfully
integrating with the Nanopore process. In order to sort each viral lineage during analysis,
unique VPN primers were made to yield barcoded sequences. The primers included a
DCV sequence from a conserved area of the genome, the VPN sequence from Nanopore,
and a custom barcode in the order: 5’ VPN-Barcode-GSP 3’. The SSP primers also
included the SSP sequence from Nanopore along with the same custom barcodes for each
lineage and methylated ribonucleotides at the end in the order: 5’ SSP-Barcode-MG 3’
(Table 1). These primers were used during the reverse transcription and strand-switching
step of the direct cDNA protocol. Native barcoding kits provided by Nanoporetech would
have involved ligating dT tailed barcode adapters after the end-prep protocol. This differs
from our process where the barcode is within the primers, added within the initial steps of
the protocol, and does not require additional steps outside of the direct cDNA protocol.
This was done to avoid an amplification step while coping with the low amount of
starting sample RNA. The unique DCV sequence also allows for more specific binding to
DCV virions only, rather than binding to all strands with polyadenylated ends. This could

29

have led to a higher number of host derived RNAs being sequenced. All sequencing steps
were completed for the initial inoculum (un-evolved). Due to the disruption caused by
COVID-19 the evolved Maur and Emel inoculums were collected and TRIzol purified
but not sequenced with the MinION device. For this reason, the hypothesis of convergent
evolution could not be tested.
Once Nanopore sequencing was completed for the unevolved inoculum using the
MinION device, the data was processed for quality as this new technology can produce
about 5% error. Therefore, only single nucleotide polymorphisms appearing in at least
5% of the reads were considered “real” and rarer single nucleotide polymorphisms were
considered error and were eliminated from the data set. The genomics of the inoculum
virions and the resulting six passaged lineages were to then be compared using MEGA
(Molecular Evolutionary Genetics Analysis) which would have produced phylogenetic
trees based on each population of sequences. By comparison of the phylogenetic
structure, this data interpretation would have identified if convergent evolution had
occurred throughout the serial passage experiment.
Data Analysis
Fitness data was analyzed using RStudio software. Poisson regression models and
estimated marginal means were used to analyze any changes in fecundity and
development for passages 1, 5, 10, and Emel infected with Maur-evolved DCV. The
average relative number of eggs, pupae, and adults were plotted for both hosts. The
relative information was completed by first calculating the average number of eggs for
each Maur and Emel control. The relative number of eggs for each sample was calculated
by dividing each sample by the average of their respective control group. This was done
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to minimize variance in the data across all the passages and to better compare the two
species as D. mauritiana is, on average, less fecund. The average of each lineage was
then calculated resulting in the average for all controls in all passage to become 1. The
same process of relative quantification was also performed for pupae and adults.
Survival analysis from the LT50 data was performed in RStudio with a rightcensored Kaplan-Meier estimates of survival curves. The associations of the survival
times were additionally analyzed using the Cox proportional-hazards model.
In the analysis of the RT-qPCR data, the amount of viral genomic RNA was
quantified relative to the amount of reference gene (RpL32). The amplification
efficiencies of each primer set were first calculated by using a 10-fold serial dilution of
the cDNA from a fly previously injected with DCV and collected at the LT50. Each 10fold dilution was completed in triplicate and the Ct values determined for each. The slope
of the Ct values was calculated in excel and added to the equation E = 10-1/slope. The
amplification efficiency was then changed to a percentage. The Pfaffl method was used to
calculate the relative quantification of virions for each sample. The formula used for
relative quantification was:

(PFAFFL 2004). Within the calculation ∆Ct(target) = Ct(DCV primer in calibrator) – Ct
(DCV primer in test) and ∆Ct(reference) = Ct(reference gene in calibrator) – Ct(reference
gene in tests). The Etarget and Ereference were the amplification efficiencies previously found
for each primer set during the 10-fold dilution series. The relative quantifications were
then analyzed in RStudio using the analysis of variance (ANOVA) method.
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Primary Nanopore sequence data was acquired using MinKNOW. The taxonomy
of each MinKNOW read from the unevolved virus was assigned using the EPI2ME
workflow FASTQ What’s In My Pot (WIMP) (nanoporetech.com). The files were later
re-base-called using the data processing toolkit Guppy v3.2.2 due to its recently increased
accuracy potential (WICK et al. 2019). Minibar demultiplexer was then used to separate
the lineages of the unevolved inoculum into individual folders based on their custom
barcodes. Completing Minibar with the unevolved inoculum provided a comparison of
the efficiency between each primer set. If the number of reads did not match between
each barcode for the unevolved data, an unequal primer efficiency is indicated which
would need to be fixed before completing the evolved analysis.
RESULTS
Measures for fecundity were collected and analyzed as a proxy for virulence. The
data included the total eggs, total pupae, total males, total females, and total adults within
each vial at passages 1, 5, and 10. The number of eggs decreased significantly for each
viral lineage of Maur and Emel from passage 1 to 5 (P < 0.001; Figure 4a). The number
of eggs were indistinguishable between passage 5 and 10 (P > 0.05; Figure 4a). There
were significantly fewer eggs in the DCV-infected Emel lineages versus Emel controls (P
< 0.001; Figure 4a). Maur females also produced significantly fewer eggs in the DCVinfected lineages when compared to the Maur controls (P < 0.001; Figure 4a). Besides
Maur A (which was excluded because the infected females failed to oviposited), there
were no significant differences in oviposition rates between the DCV-infected lineages of
Maur and Emel (P > 0.05; Figure 4a). Analysis of total pupae reflected the decrease in
fecundity. All DCV-infected lineages experienced a significant decline in the number of
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pupae produced from passage 1 to 5 similar to the decrease in the number of eggs
observed for each Maur and Emel DCV-infected lineages (P < 0.001; Figure 4b). The
total number of pupae was indistinguishable from SP5 to SP10 (P > 0.05; Figure 4b). The
exception was lineage Maur A which had significantly more pupae than Maur C in
passage 1, but still significantly fewer than the Maur control (P < 0.001; Figure 4b).
The number of male and female offspring were counted 21 days after injection
with DCV or the Schneider’s medium control. Schneider’s-injected control flies had
significantly more male offspring (P < 0.001; Figure 4c). Except for the removed Maur A
in passage 5, there was no strong species effect for male offspring number (P > 0.05;
Figure 4c). At passage 1, there were no differences in the number of males between
lineages of DCV-infected Emel, but there were significantly more males in Maur A than
Maur C (P = 0.025). The total number of males decreased for all DCV-infected lineages
of Maur from passage 1 to 5 (P < 0.001; Figure 4c). The number of males in DCVinfected Emel A, B, and C also significantly decreased from passage 1 to 5 (P < 0.001;
Figure 4c). The number of males decreased significantly in DCV-infected lineages for all
but Emel A from passage 1 to 10 (P < 0.001; Figure 4c). The total number of females
decreased for all DCV-infected lineages but Emel B from passage 1 to 5 (P < 0.001;
Figure 4c). Similar to the male data, the number of females declined for all DCV-infected
lineages of Maur and Emel from passage 1 to 10 (P < 0.002; Figure 4c). The total number
of females was indistinguishable between species for DCV-infected lineages at each
passage (P > 0.05; Figure 4c).
Lastly we examined the total number of adults in the initial vials after injection
(non-green A vials) counted on day 21. A sharp decline in adults was observed from
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passage 1 to 5 for each lineage of DCV-infected Maur and Emel (P < 0.001; Figure 4d).
The number of adults from passage 5 to 10 also significantly decreased from passage 5 to
10 for all lineages, except Maur C (P < 0.007; Figure 4d). The number of adults in Maur
C was indistinguishable between passage 5 and 10 (P = 0.8980; Figure 4d). Each control
contained more adults after 21 days than each of the DCV-infected treatments at each
passage (P < 0.001; Figure 4d).
Developmental timing was examined at passages 1, 5, and 10. The days to form
the first pupa and the days to first adult emergence were determined for each vial of
injected and control flies. There were no significant differences in developmental timing
across species or treatments (P > 0.05; Figure 5).
Fly mortality was used as an additional proxy for virulence. Mortality was
recorded daily for each lineage until half of all flies were dead in each lineage (LT50) or
until 10 days post injection passed. The survival analysis showed no differences in the
LT50 for any DCV-infected lineages from passage 1 to 10 (P > 0.05; Figure 6). An
additional analysis using the Cox proportional-hazards model suggested a significantly
higher probability of dying if flies were in the DCV-infected Maur lineages compared to
Emel lineages and the control groups (P < 0.001; Figure 7; Figure 8). Conversely,
Drosophila injected with Schneider’s medium had a greater probability of surviving (P <
0.001; Figure 7; Figure 8).
Emel infected with Maur-evolved DCV was utilized to test whether the Maurevolved DCV (collected at the LT50 of passage 10) was less able to infect the native
host. The Maur-evolved virus was injected into the naïve native host Emel and compared
to Emel passage 1. The same measures for fecundity and development as passage 1 were
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determined (total eggs, total pupae, total males, total females, total adults, days to pupae,
and days to adult). As expected, the flies injected with Maur-evolved DCV laid
significantly fewer eggs than the Schneider’s-injected controls (P < 0.001; Figure 9a). No
distinguishable difference between Maur-evolved DCV-infected lineages were noted (P >
0.05; Figure 9a). The flies injected with Maur-evolved DCV produced significantly fewer
eggs than the flies injected with ancestral DCV (P < 0.001; Figure 9a). Concomitantly,
there were significantly higher numbers of total pupae, total males, total females, and
total adults in Emel SP1 compared to Maur-evolved infected Emel (P < 0.001; Figure 9b;
Figure 9c; Figure 9d). The number of days to pupae formation or days to adult emergence
were indistinguishable between Emel SP1 and the Emel infected with Maur-evolved
inoculum (P > 0.05; Figure 10).
The final analysis for the Maur-evolved infected Emel was survival using the day
each fly died until the LT50 was reached or 10 days post injection. No significant
changes were noted from the ancestral injected Emel at passage 1 to the Maur-evolved
infected Emel (P > 0.05; Figure 11).
The 10-fold dilution series for the qPCR primers indicated the amplification
efficiency for each primer set fell between 90-110% and were deemed optimal; however,
there was an 8% difference between the amplification efficiency of the DCV primers and
RpL32 gene primers. The Pfaffl method to calculate the virion load was chosen to
accommodate the 8% amplification efficiency difference. A three-way ANOVA between
passages, species, and lineages was completed in RStudio to analyze the qPCR data.
Although several infected Maur flies had very high titer loads when compared to infected
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Emel, there were no significant differences in the viral load among flies from passages 1
to 5, 5 to 10, or 1 to 10 for any of the DCV-infected lineages (P > 0.05; Figure 12).
A total of 22.52K unique sequences and 34.85 megabases were read by
MinKNOW from the Nanopore sequencing run using the unevolved inoculum viral RNA.
The estimated N50, the length of the shortest contig at 50% of the total genome length,
was 3.55Kb. EPI2ME analyzed 11,981 reads with 10,882 of those classified into one
taxon. A high percentage (95%) were classified as a virus totaling 10,354 of the 10,882
classified reads within the Cripavirus genus, of which DCV is a member (Figure 13).
The custom barcodes within the SSP and VNP primers were tested using the
unevolved inoculum RNA in Nanopore sequencing. The number of reads was lower than
expected. Just under 11,000 reads were successfully sequenced. Of those, 95% were
DCV. The remaining reads appear to be some form of contamination. Demultiplexing of
the barcodes was successful using Minibar indicating that our method of putting the
barcodes into the strand switching primers is a viable methodology. However, the number
of sequences within each barcode group was unbalanced (Table 2). Three of the barcodes
contained enough reads to move to the next step of variant calling, but the other three had
too low of coverage to enable the variant calling process. There were reads that only
contained a barcode on either the 5’ or the 3’ end instead of at both ends, as was
expected. More specifically, many of the reads appear to begin or end at the unique DCV
sequence suggesting the VNP primer worked. The SSP primer appears to have bound
non-specifically to internal portions of DCV.
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DISCUSSION
Serial passaging experiments have been utilized for the study of host shifts but
these are usually done with bacterial hosts and low virulence phage pathogens (BULL
1994; EBERT 1998). Using Drosophila in SPE experiments should give a more accurate
representation as to how a complex host will respond to a host shift (GALIANA-ARNOUX
et al. 2006b; BRUSINI et al. 2013). It can also illustrate that complex hosts will not always
react as predicted by standard SPE experiments (BRUSINI et al. 2013). Using DCV, a
highly virulent pathogen, provides insight into how such a pathogen might behave after a
host shift.
The fecundity analysis demonstrated that DCV infection caused a sudden and
sharp decrease in the number of eggs oviposited, the number of pupae formed, and the
number of emerging adults for both the native and the novel host. This result suggests
that the virus is equally virulent on the native and novel hosts. The decreased fecundity in
both the native and novel host could be explained by the initiation of the innate immune
response. While Drosophila have some means to fight a DCV infection, the use of the
immune response may come as a cost to fitness (MCKEAN et al. 2008). Previous host
shift experiments using DCV and Drosophila have demonstrated similar decreases in
fitness for Drosophila melanogaster. The study by E. Hendrix in 2018 described
metabolomic differences between the native and novel host which suggested the native
host was better suited to regulate the DCV infection (LONGDON et al. 2015; HENDRIX
2018). Based on this information, we would have expected a larger decrease in fecundity
of DCV-infected D. mauritiana at SP1 in comparison to the native host. The differences
in virulence between Hendrix and the current study might be due to differences in
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virulence of the original inoculum. Although the inocula were sourced from the same lab,
they were produced in different batches several years apart.
The virus significantly increased in virulence early within the passaging
experiment for both hosts. Also, while both hosts experienced a decrease in fecundity, the
survivability analysis suggested the native host was still better suited to handle the DCV
infection. This is in agreement with the findings from Hendrix 2018 (HENDRIX 2018).
The flies within the control treatments lived longer than both Maur and Emel, but Maur
lineages reached their LT50 points significantly sooner than Emel at each passage. The
longer survivability times of Emel could be explained by the coevolution that has
occurred between DCV and Emel. For this reason, the native host may be better equipped
to recognize infection and adjust to survive longer than the novel host (LONGDON et al.
2015; HENDRIX 2018). Previous studies with D. melanogaster and D. mauritiana support
this finding. A previous host shift experiment suggested the two species of Drosophila
regulate their metabolites differently with the novel host less able to cope with the DCV
infection (HENDRIX 2018). The DCV virulence increase in the novel host supports the
bacterial SPE hypothesis, but the significant increase in the native host was not expected
since DCV is found to infect D. melanogaster in nature (EBERT 1998; LONGDON et al.
2015). The high starting virulence of DCV on the native host could explain this result
(JOUSSET et al. 1977). The majority of previous host shift experiments have been
performed using pathogens that naturally have low native host virulence (BULL 1994).
Additionally, the decrease in fecundity but unchanged survival times could indicate a
balance between reproduction and survivability occurring within the native host. This
could again be a coping mechanism by Drosophila to reallocate energy for immune
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response assistance found in other Drosophila studies (MORET and SCHMID-HEMPEL
2000; LONGDON et al. 2015; HENDRIX 2018).
The transmission mode could also be influencing these results. Pathogens
utilizing vertical transmission alone favor a decrease in virulence over time. Contrary to
this, pathogens that normally cause minor harm to the host have shown sudden increases
in virulence after only a few horizontal passages (ANTONOVICS et al. 2017; LE CLEC'H et
al. 2017). While vertical transmission relies on the host’s offspring to survive,
horizontally-transmitted pathogens may have the ability to evolve quickly without the
need for host offspring (ANTONOVICS et al. 2017). For our study, utilizing artificial
injection resulted in guaranteed horizontal transmission. This could have caused a
selective advantage for the more virulent strains of DCV without the limiting step of
requiring the host to survive long enough to complete successful transmission to the next
host (LIPSITCH et al. 1995; ANTONOVICS et al. 2017). To mitigate the experimenter’s
influence on the artificial injecting process, the viral dose from one passage to the next
was not controlled allowing the virion load to change naturally.
The decreases in fecundity for each lineage of Maur and Emel from passage 1 to
10 indicates the virulence of DCV increased on both the native and novel host. However,
the viral titers did not change significantly to explain the increase in virulence. The
pathogen appeared to increase in virulence without needing to produce a higher number
of virions. Other serial passaging studies completed with Drosophila and the vertically
transmitted Sigma virus have suggested opposite effects (LONGDON et al. 2011a). A study
performed by Londgon et al. 2015 showed an increase in viral load that correlated with
increases in virulence. The viral titer had an even more prominent increase between
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species of Drosophila that were closely related such as D. melanogaster and D.
mauritiana (LONGDON et al. 2015). Based on these studies, and a number of others that
have also found high viral titers that parallel increased virulence, we would have
expected to see an increasing DCV viral load within this experiment (BRUSINI et al. 2013;
LONGDON et al. 2015). The major difference here is that DCV is a highly virulent
horizontally transmitted pathogen as opposed to the pathogen used in these previous
studies (Sigma rhabdovirus) which is a vertically transmitted pathogen with minimal
virulence. Thus the mechanism by which DCV’s virulence increased remains unclear.
The virus evolved on the novel host was more virulent to naïve native hosts
(Emel) than the ancestral virus. Testing the hypothesis that the novel evolved virus would
be less virulent on the native host was not supported based on the observed decrease in
fecundity. The naïve native hosts produced significantly fewer eggs, pupae, and adults
when injected with the Maur-evolved virus in comparison to injection with the original
DCV inoculum. Other host shift studies have found a decrease in the ability of the
pathogen to infect the native host once it is better suited to infect the novel host (EBERT
1998). This contrasts with our results. The species Maur and Emel are closely related so
they could share similar pathways which allowed DCV to evolve within Maur while
remaining equally able to infect and kill Emel using similar mechanisms (CLARK et al.
2007; CHANG et al. 2016). Additionally, DCV is highly virulent to its native host and it’s
possible that after many more passages the virus would have become less virulent on the
native host.
Testing of convergent evolution could not be completed due to disruptions caused
by COVID-19. This could have helped to explain whether the Maur-evolved DCV
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experienced paralleled changes within each lineage suggesting a specific variant that was
best able to survive in the new host environment (DOMINGO and HOLLAND 1997).
Previous studies have shown specific genotypes become more prominent each time a
shift from the native to novel host occurs and contribute positively to how the pathogen
performs on the novel host (VERTACNIK and LINNEN 2017; LONGDON et al. 2018). The
differing unevolved barcoding results could have occurred due to sample fragmentation
during the sample preparation process. The VNP primers appear to successfully bind to
the complimentary unique DCV sequence within the virions but many of the SSP primers
bound nonspecifically to internal portions of DCV. Thus, in future experiments new SSP
primers need to be designed and/or the priming conditions need to be optimized. It is
difficult to discern the source of the variance in the number of each barcode present in the
read pool, given the overall low number of reads. It is likely that the low number of reads
can be ameliorated by improving the design of the sequence-specific region of the SSP
primer.
Disease emergence in novel hosts are often associated with a pathogen’s ability to
adapt to said host. Understanding these mechanisms can have important implications to
predicting or even preventing outbreaks (DOWLING et al. 2020). Many of these host shift
findings have been done using bacteria and with low virulence pathogens in SPEs. Our
study compared those findings to a more complex host, Drosophila, and a highly virulent
pathogen. Similar to bacterial SPEs, the pathogen did increase in virulence on the novel
host following the host shift even though the virus was already highly virulent to the
native host (BULL 1994; EBERT 1998). However, the evolved virus was still able to
significantly decrease the fecundity of the native host, not matching bacterial SPE
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predictions. This suggests some of these bacterial hypotheses may still hold with complex
organisms and with high virulence pathogens. These findings could benefit from
additional metabolomic and proteomic analysis along with immune markers via RTqPCR. Such work would aide in further elucidation of the host species’ responses in
reaction to changes in virulence by the virus. Our results highlight the importance of
performing SPEs using more complex host organisms and pathogens with varying
degrees of virulence on the native host so that we can continue improving our
understanding of pathogen virulence following a host shift.
At present, the human population is experiencing a host-shift event with SARSCoV-2 the likes of which has not been seen in the human population in a very long time.
This event clearly illustrates the need for continued study of host shifts and virulence
evolution following such that we may eventually be able to predict and possibly prevent
future host shifts and the resulting pandemics.

42

REFERENCES CITED
Adams, M. D., S. E. Celniker, R. A. Holt, C. A. Evans, J. D. Gocayne et al., 2000 The
genome sequence of Drosophila melanogaster. Science: 2185-2195.
Ahmed, A. M., S. L. Baggott, R. Maingon and H. Hurd, 2002 The costs of mounting an
immune response are reflected in the reproductive fitness of the mosquito
Anopheles gambiae. Oikos: 371-377.
Alizon, S., A. Hurford, N. Mideo and M. Van Baalen, 2009 Virulence evolution and the
trade-off hypothesis: history, current state of affairs and the future. J. Evol. Biol. :
245-259.
Antonovics, J., A. J. Wilson, M. R. Forbes, H. C. Hauffe, E. R. Kallio et al., 2017 The
evolution of transmission mode. Philos. Trans. R. Soc. Lond., B, Biol. Sci.: 12.
Best, A., A. White and M. Boots, 2014 The coevolutionary implications of host tolerance.
Evolution: 1426-1435.
Betts, A., C. Gray, M. Zelek, R. C. MacLean and K. C. King, 2018 High parasite
diversity accelerates host adaptation and diversification. Science: 907-+.
Bier, E., M. M. Harrison, K. M. O'Connor-Giles and J. Wildonger, 2018 Advances in
engineering the fly genome with the CRISPR-Cas system. Genetics: 1-18.
Bonneaud, C., M. Giraudeau, L. Tardy, M. Staley, G. E. Hill et al., 2018 Rapid
antagonistic coevolution in an emerging pathogen and its vertebrate host. Curr.
Biol: 2978-+.
Brusini, J., Y. Wang, L. Matos, L. Sylvestre, B. Bolker et al., 2013 Virulence evolution
in a host-parasite system in the absence of viral evolution. Evol. Ecol. Res.: 883901.
Bull, J., 1994 Perspective: virulence. Evolution: 1423-1437.
Chang, T. C., A. Salvucci, P. W. Crous and I. Stergiopoulos, 2016 Comparative
genomics of the Sigatoka disease complex on banana suggests a link between
parallel evolutionary changes in Pseudocercospora fijiensis and
Pseudocercospora eumusae and increased virulence on the banana host. Plos
Genet.: 35.
Cherry, S., and N. Perrimon, 2004 Entry is a rate-limiting step for viral infection in a
Drosophila melanogaster model of pathogenesis. Nat. Immunol.: 81-87.
Chintapalli, V. R., J. Wang and J. A. T. Dow, 2007 Using FlyAtlas to identify better
Drosophila melanogaster models of human disease. Nat. Genet.: 715-720.
Clark, A. G., M. B. Eisen, D. R. Smith, C. M. Bergman, B. Oliver et al., 2007 Evolution
of genes and genomes on the Drosophila phylogeny. Nature: 203-218.
Cleaveland, S., M. K. Laurenson and L. H. Taylor, 2001 Diseases of humans and their
domestic mammals: pathogen characteristics, host range and the risk of
emergence. Philos. Trans. R. Soc. Lond. Ser. B-Biol. Sci.: 991-999.

43

Coronaviridae Study, G., 2020 The species Severe acute respiratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature
Microbiology 5: 536-544.
Dennehy, J. J., N. A. Friedenberg, R. D. Holt and P. E. Turner, 2006 Viral ecology and
the maintenance of novel host use. Am. Nat.: 429-439.
Desjardins, C. A., C. Giamberardino, S. M. Sykes, C. H. Yu, J. L. Tenor et al., 2017
Population genomics and the evolution of virulence in the fungal pathogen
Cryptococcus neoformans. Genome Res.: 1207-1219.
Domingo, E., and J. J. Holland, 1997 RNA virus mutations and fitness for survival.
Annu. Rev. Microbiol.: 151-178.
Dowling, A., G. Hill and C. Bonneaud, 2020 Multiple differences in pathogen-host cell
interactions following a bacterial host shift. Scientific Reports 10.
Drake, J. W., and J. J. Holland, 1999 Mutation rates among RNA viruses. Proc. Natl.
Acad. Sci. U.S.A.: 13910-13913.
Duffy, S., L. A. Shackelton and E. C. Holmes, 2008 Rates of evolutionary change in
viruses: patterns and determinants. Nat. Rev. Genet.: 267-276.
Duneau, D., J. B. Ferdy, J. Revah, H. Kondolf, G. A. Ortiz et al., 2017 Stochastic
variation in the initial phase of bacterial infection predicts the probability of
survival in D. melanogaster. Elife: 23.
Ebert, D., 1998 Evolution - experimental evolution of parasites. Science: 1432-1435.
Ellison, A. R., G. V. DiRenzo, C. A. McDonald, K. R. Lips and K. R. Zamudio, 2017
First in vivo Batrachochytrium dendrobatidis transcriptomes reveal mechanisms
of host exploitation, host-specific gene expression, and expressed genotype shifts.
G3-Genes Genomes Genet.: 269-278.
Ewald, P. W., 1983 Host-parasite relations, vectors, and the evolution of disease severity.
Annu. Rev. Ecol. Evol. Syst.: 465-485.
Frank, S., 1996 Models of parasite virulence. Q. Rev. Biol.: 37-78.
Galiana-Arnoux, D., C. Dostert, A. Schneemann, J. A. Hoffmann and J. L. Imler, 2006a
Essential function in vivo for Dicer-2 in host defense against RNA viruses in
drosophila. Nature Immunology 7: 590-597.
Galiana-Arnoux, D., C. Dostert, A. Schneemann, J. A. Hoffmann and J. L. Imler, 2006b
Essential function in vivo for Dicer-2 in host defense against RNA viruses in
Drosophila. Nat. Immunol.: 590-597.
Giot, L., J. S. Bader, C. Brouwer, A. Chaudhuri, B. Kuang et al., 2003 A protein
interaction map of Drosophila melanogaster. Science: 1727-1736.
Gomez, P., B. Ashby and A. Buckling, 2015 Population mixing promotes arms race hostparasite coevolution. Proc. R. Soc. B-Biol. Sci.: 8.
Group, C. S., 2020 The species Severe acute respiratory syndrome-related coronavirus:
classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 5: 536544.

44

Hendrix, E. K., 2018 Characterizing the early stages of a novel host shift using host
fitness and metabolomics, pp., EWU Masters Thesis Collection.
Hoberg, E. P., and D. R. Brooks, 2015 Evolution in action: climate change, biodiversity
dynamics and emerging infectious disease. Philos. Trans. R. Soc. B-Biol. Sci.: 7.
Howard, C. R., and N. F. Fletcher, 2012 Emerging virus diseases: can we ever expect the
unexpected? Emerg. Microbes Infect.: 11.
Jansen, G., L. L. Crummenerl, F. Gilbert, T. Mohr, R. Pfefferkorn et al., 2015
Evolutionary transition from pathogenicity to commensalism: global regulator
mutations mediate fitness gains through virulence attenuation. Mol. Biol. Evol.:
2883-2896.
Jousset, F., M. Bergoin and B. Revet, 1977 Characterization of the Drosophila C virus. J.
Gen. Virol.: 269-285.
Le Clec'h, W., J. Dittmer, M. Raimond, D. Bouchon and M. Sicard, 2017 Phenotypic
shift in Wolbachia virulence towards its native host across serial horizontal
passages. Proc. R. Soc. B-Biol. Sci.: 10.
Levin, B., 1996 The evolution and maintenance of virulence in microparasites. Emerg.
Infect. Dis.: 93-102.
Licht, H. H. D., 2018 Does pathogen plasticity facilitate host shifts? Plos Pathog.: 9.
Linde, J., S. Duggan, M. Weber, F. Horn, P. Sieber et al., 2015 Defining the
transcriptomic landscape of Candida glabrata by RNA-Seq. Nucleic Acids Res.:
1392-1406.
Lipsitch, M., M. A. Nowak, D. Ebert and R. M. May, 1995 The population dynamics of
vertically and horizontally transmitted parasites. Proc. R. Soc. B-Biol. Sci.: 321327.
Lipsitch, M., S. Siller and M. A. Nowak, 1996 The evolution of virulence in pathogens
with vertical and horizontal transmission. Evolution: 1729-1741.
Little, T. J., K. Watt and D. Ebert, 2006 Parasite-host specificity: experimental studies on
the basis of parasite adaptation. Evolution: 31-38.
Longdon, B., J. P. Day, J. M. Alves, S. C. L. Smith, T. M. Houslay et al., 2018 Host
shifts result in parallel genetic changes when viruses evolve in closely related
species. Plos Pathog.: 14.
Longdon, B., J. D. Hadfield, J. P. Day, S. C. L. Smith, J. E. McGonigle et al., 2015 The
causes and consequences of changes in virulence following pathogen host shifts.
Plos Pathog.: 18.
Longdon, B., J. D. Hadfield, C. L. Webster, D. J. Obbard and F. M. Jiggins, 2011a Host
phylogeny determines viral persistence and replication in novel hosts. Plos
Pathog.: 9.
Longdon, B., L. Wilfert, J. Osei-Poku, H. Cagney, D. J. Obbard et al., 2011b Hostswitching by a vertically transmitted rhabdovirus in Drosophila. Biol. Lett.: 747750.

45

Lubinski, J., L. Y. Wang, D. Mastellos, A. Sahu, J. D. Lambris et al., 1999 In vivo role of
complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Journal of Experimental Medicine 190: 1637-1646.
Mackinnon, M. J., and A. F. Read, 2004 Immunity promotes virulence evolution in a
malaria model. Plos Biol.: 1286-1292.
May, R. M., and R. M. Anderson, 1983 Epidemiology and genetics in the coevolution of
parasites and hosts. Proc. R. Soc. B-Biol. Sci.: 281-313.
McKean, K. A., C. P. Yourth, B. P. Lazzaro and A. G. Clark, 2008 The evolutionary
costs of immunological maintenance and deployment. Bmc Evolutionary Biology
8.
Monsanto-Hearne, V., and K. N. Johnson, 2018 Wolbachia-mediated protection of
Drosophila melanogaster against systemic infection with its natural viral pathogen
Drosophila C virus does not involve changes in levels of highly abundant
miRNAs. Journal of General Virology 99: 827-831.
Moret, Y., and P. Schmid-Hempel, 2000 Survival for immunity: The price of immune
system activation for bumblebee workers. Science 290: 1166-1168.
Morley, V. J., S. Y. Mendiola and P. E. Turner, 2015 Rate of novel host invasion affects
adaptability of evolving RNA virus lineages. Proc. R. Soc. B-Biol. Sci.: 7.
Nam, J. H., S. M. Shim, E. J. Song, E. Espano, D. G. Jeong et al., 2017 Rapid virulence
shift of an H5N2 avian influenza virus during a single passage in mice. Arch.
Virol.: 3017-3024.
Osborne, S. E., Y. S. Leong, S. L. O'Neill and K. N. Johnson, 2009 Variation in antiviral
protection mediated by different Wolbachia strains in Drosophila simulans. Plos
Pathog.: 9.
Parker, I. M., and G. S. Gilbert, 2004 The evolutionary ecology of novel plant-pathogen
interactions. Annu. Rev. Ecol. Evol. Syst.: 675-700.
Patz, J. A., T. K. Graczyk, N. Geller and A. Y. Vittor, 2000 Effects of environmental
change on emerging parasitic diseases. Int. J. Parasitol: 1395-1405.
Pfaffl, M. W., 2004 Quantification strategies in real-time PCR, pp. 87-112 in A-Z of
quantitative PCR, edited by S. A. Bustin. International University Line.
Ponton, F., M. P. Chapuis, M. Pernice, G. A. Sword and S. J. Simpson, 2011 Evaluation
of potential reference genes for reverse transcription-qPCR studies of
physiological responses in Drosophila melanogaster. J. Insect Physiol.: 840-850.
Regoes, R. R., M. A. Nowak and S. Bonhoeffer, 2000 Evolution of virulence in a
heterogeneous host population. Evolution: 64-71.
Rogalski, M. A., C. D. Gowler, C. L. Shaw, R. A. Hufbauer and M. A. Duffy, 2017
Human drivers of ecological and evolutionary dynamics in emerging and
disappearing infectious disease systems. Philosophical Transactions of the Royal
Society B-Biological Sciences 372: 9.

46

Sabatier, L., E. Jouanguy, C. Dostert, D. Zachary, J. L. Dimarcq et al., 2003 Pherokine -2
and -3: two Drosophila molecules related to pheromone/odor-binding proteins
induced by viral and bacterial infections. Eur. J. Biochem.: 3398-3407.
Sharp, P. M., and B. H. Hahn, 2011 Origins of HIV and the AIDS Pandemic. Cold Spring
Harbor Perspectives in Medicine 1: 22.
Shin, J., and T. MacCarthy, 2016 Potential for evolution of complex defense strategies in
a multi-scale model of virus-host coevolution. BMC Evol. Biol.: 15.
Silva, W. M., F. A. Dorella, S. C. Soares, G. Souza, T. L. P. Castro et al., 2017 A shift in
the virulence potential of Corynebacterium pseudotuberculosis biovar ovis after
passage in a murine host demonstrated through comparative proteomics. BMC
Microbiol.: 14.
van den Bosch, F., B. A. Fraaije, F. van den Berg and M. W. Shaw, 2010 Evolutionary
bi-stability in pathogen transmission mode. Proc. R. Soc. B-Biol. Sci.: 1735-1742.
van Sluijs, L., G. P. Pijlman and J. E. Kammenga, 2017 Why do individuals differ in viral
susceptibility? a story told by model organisms. Viruses-Basel: 13.
VanGuilder, H. D., K. E. Vrana and W. M. Freeman, 2008 Twenty-five years of
quantitative PCR for gene expression analysis. Biotechniques: 619-626.
Vertacnik, K. L., and C. R. Linnen, 2017 Evolutionary genetics of host shifts in
herbivorous insects: insights from the age of genomics. Ann. N.Y. Acad. Sci.:
186-212.
Watanabe, S., J. S. Masangkay, N. Nagata, S. Morikawa, T. Mizutani et al., 2010 Bat
Coronaviruses and Experimental Infection of Bats, the Philippines. Emerging
Infectious Diseases 16: 1217-1223.
Wick, R. R., L. M. Judd and K. E. Holt, 2019 Performance of neural network basecalling
tools for Oxford Nanopore sequencing. Genome Biology 20: 129.
Woolhouse, M. E. J., and S. Gowtage-Sequeria, 2005 Host range and emerging and
reemerging pathogens. Emerg. Infect. Dis.: 1842-1847.

47

TABLES
Table 1: The custom primers used for the Nanopore direct cDNA protocol during
Nanopore sequencing. Each VPN primer included a unique DCV sequence along with the
VPN sequence found on the Nanopore website and a custom barcode. The SSP primers
included the SSP sequence recommended by Nanopore along with a custom barcode for
each lineage.
Primer
VPN-Maur A
VPN-Maur B
VPN-Maur C
VPN-Emel A
VPN-Emel B
VPN-Emel C
SSP-Maur A
SSP-Maur B
SSP-Maur C
SSP-Emel A
SSP-Emel B
SSP-Emel C

Primer Sequence 5'-3'

Barcode

ACTTGCCTGTCGCTCTATCTTCCAACTTTCTTCATCGAATTGCCAAAACCGC
ACTTGCCTGTCGCTCTATCTTCAACCAAGACTCATCGAATTGCCAAAACCGC
ACTTGCCTGTCGCTCTATCTTCGAGAGGACAACATCGAATTGCCAAAACCGC
ACTTGCCTGTCGCTCTATCTTCGTTCCCTGAACATCGAATTGCCAAAACCGC
ACTTGCCTGTCGCTCTATCTTCAAAGGTTTCACATCGAATTGCCAAAACCGC
ACTTGCCTGTCGCTCTATCTTCGGTTTGTTCCCATCGAATTGCCAAAACCGC
TTTCTGTTGGTGCTGATATTGCTCAACTTTCTTmGmGmG
TTTCTGTTGGTGCTGATATTGCTAACCAAGACTmGmGmG
TTTCTGTTGGTGCTGATATTGCTGAGAGGACAAmGmGmG
TTTCTGTTGGTGCTGATATTGCTGTTCCCTGAAmGmGmG
TTTCTGTTGGTGCTGATATTGCTAAAGGTTTCAmGmGmG
TTTCTGTTGGTGCTGATATTGCTGGTTTGTTCCmGmGmG

CAACTTTCTT
AACCAAGACT
GAGAGGACAA
GTTCCCTGAA
AAAGGTTTCA
GGTTTGTTCC
CAACTTTCTT
AACCAAGACT
GAGAGGACAA
GTTCCCTGAA
AAAGGTTTCA
GGTTTGTTCC
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Table 2: The number of reads per barcode was very uneven in the data. Using Minibar,
the total number of reads identified by Minibar with their designated custom barcodes on
both the 5’ and 3’ ends are listed in the first second column of the table. There were also
reads that contained a barcode on either the 5’ or 3’ end rather than both. Two barcodes
were present on a higher number of total reads when compared to the other barcodes.
Barcode

Total reads: both 5' and 3'
barcodes present
GTTCCCTGAA
6
AAAGGTTTCA
8
GGTTTGTTCC
2
CAACTTTCTT
0
AACCAAGACT
63
GAGAGGACAA
125

Total reads: 5' or 3'
barcode
4
7
1
0
21
21
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FIGURES

Figure 1. Serial passage experiment setup schematic. The passage process started by
injecting naïve native and novel hosts with DCV inoculum generated in cell culture. A
unique evolved DCV inoculum was then used for each lineage after passage 1. The
inoculum was obtained by homogenizing 10 of the surviving native or novel hosts
collected at the LT50 or day 10 for each viral lineage. For example, the homogenate from
passage 1 Emel A was injected into naïve Emel A to start 2. This process was repeated
for each viral lineage until 10 serial passages were completed. Each of the 3 viral lineages
within each species is indicated by a different color.
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Figure 2. Analysis setup during serial passage experimentation. DCV inocula were
generated from the native and novel host at the LT50 point and injected into a new set of
naïve hosts. The viral titer at the LT50 point was measured using RT-qPCR at serial
passages 1, 5, and 10. The host fitness was analyzed at serial passages 1, 5, and 10 using
fly fecundity and development as proxies for virulence. Nanopore sequencing was
completed on the ancestral DCV before serial passaging. Because of disruptions due to
COVID-19 the evolved virus was not sequenced, and the hypothesis of convergent
evolution was not tested.

51

Figure 3: General schematic for the fitness analyses setup performed at passages 1, 5, 10,
and Maur-evolved infected Emel. Immediately after injection with DCV or control
media, each fly was placed in an individual vial (A) and a non-injected male was added.
After 24hrs each set of flies was flipped to a new individual vial with green-tinted media
(B), allowed to lay, and flipped back to the original vial (A) after 24 hours. The
hatchability assay included counting the number of eggs oviposited after 24 hours on the
green-tinted vial (B) then counting the number of unhatched eggs after 48 hours. The
development assay included monitoring the number of days to first pupa formation and
the days for the first adult to emerge in each vial (B). The total number of pupae were
also counted after 10 days along with the number of females and males after 21 days in
each vial (B). The total number of adults in each vial (A) were counted after 21 days.
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Figure 4a-d: The number of eggs, pupae, and adults decreased for each lineage of Maur
and Emel. The relative numbers for each measure of fecundity were calculated from the
green tinted vials at SP1, 5, and 10. Both hosts showed significant decreases in eggs
oviposited from SP1 to SP5 (P < 0.001; Figure 4a). The number of eggs between passage
5 and 10 were indistinguishable for each lineage (P > 0.05; Figure 4a). The relative
number of pupae and adults in the green-tinted vials (B) also experienced significant
decreases in numbers from SP1 to SP5 (P < 0.001; Figure 4b; Figure 4c). There were
similarly no significant changes in the number of pupae or adults from SP5 to SP10 (P >
0.05; Figure 4b; Figure 4c). The relative number of adults was also measured from the
initial tan vials (A) at SP1, 5, and 10 shown in Figure 4d. The fecundity of the two host
species significantly decreased from SP1 to SP5 based on the number of adults (P <
0.001; Figure 4d). All but Maur C also showed a significant decrease in adults from SP5
to SP10 (P < 0.007; Figure 4d). Passage Maur C was indistinguishable between passage 5
and 10 (P = 0.8980; Figure 4d). Each measure of fecundity showed significant declines
already by passage 5.
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Figure 5: No significant differences in days to adult were found for Maur or Emel
between passages (P > 0.05). The times to adult were measured from the green tinted
vials (B) at SP1, 5, and 10. Maur A SP5 has not been included because the infected
females failed to oviposited.
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Figure 6: The probability of surviving did not change from passage 1 to 10 (P > 0.05). A
right-censored Kaplan-Meier estimate of survival curves was used to analyze the
probability of survival for each lineage over the serial passaging experiment. No
significant changes in survivability were discovered for any lineage (P > 0.05). This
means, even though pathogen virulence increased the flies did not die significantly faster
within their respective lineages.
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Figure 7: DCV was significantly more virulent on the novel host Maur (P < 0.001). A
right-censored Kaplan-Meier estimate of survival curves was used to analyze the
probability of survival between each species and treatment (control vs DCV injection).
Flies within the Maur lineages had a significantly higher probability of dying sooner than
Emel lineages and the control treatments (P < 0.001). If the Drosophila were part of the
control treatments for both species, they had a higher probability of surviving (P <
0.001). There is a species and treatment effect on survivability.

56

Figure 8. Lineages of Maur had a higher probability of dying while the control treatment
groups had a higher probability of surviving (P < 0.001). This graph represents the odds
ratio of dying for each lineage and for the total flies within each passage. It uses the day
each fly died until the LT50 point or 10 days was reached in order to calculate this ratio.
The horizontal bars represent the 95% confidence intervals. These ratios are in
comparison to Emel A. Anything in blue indicates a higher probability of dying while the
points in red indicate a lower probability compared to Emel A.
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Figure 9a-d. The decrease in fecundity suggests that the Maur-evolved DCV was more
virulent on the native host than the ancestral DCV. The Maur-evolved DCV collected
from passage 10 was injected into naïve native hosts, Emel, in order to test whether the
novel evolved virus would be less virulent on the native host. The changes in fecundity
relative to their respective controls are shown in Figures a-d. There were significantly
fewer eggs counted in Emel infected with Maur-evol DCV when compared to Emel
passage 1 (P < 0.001; Figure 9a). Significantly fewer pupae and total adults in both vials
A and B (initial tan vials and green-tinted vials) were found in Maur-evol DCV infected
Emel versus initial DCV inoculum Emel in passage 1 (P < 0.001; Figure 9b; Figure 9c;
Figure 9d). The novel evolved virus appears to still be able to significantly decrease the
fecundity of the native host.
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Figure 10. The days to adult emergence was not significantly different between Emel
passage 1 and the Emel infected with Maur-evolved DCV (P > 0.05). The average days to
adult for each DCV-infected lineage and control are represented in Figure 10. When the
naïve native hosts were injected with the novel evolved virus, the development time in
order to reach adults emergence did not appear to be affected. This suggests while the
Maur-evolved DCV lowered the fecundity of Emel, the development times did not
change.
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Figure 11. The survivability of Emel flies infected with Maur-evolved inoculum was like
Emel passage 1 (P > 0.05). A right-censored Kaplan-Meier estimate of survival curves
was used to analyze the probability of survival for each lineage of Maur-evol infected
Emel compared to Emel SP1. Injection of naïve native hosts with the Maur-evolved virus
did not appear to shorten the survival time when compared to Emel infected with the
initial DCV inoculum.
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Figure 12. The relative quantification of DCV viral titer did not change from passage 1 to
5 or from passage 5 to 10 (P > 0.05).There was also no significant difference in viral titer
between the native and novel host (P > 0.05). The DCV viral load was measured for each
sample relative to the housekeeping gene RpL32 during RT-qPCR. The fecundity of each
lineage showed a significant decrease from passage 1 to 10, but the viral titer does not
suggest an increase or decrease in DCV viral load.
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Figure 13. Analysis of nanopore sequencing indicated that our sequencing was successful
as EPI2ME classified 95% of sequences as viral. More specifically 10,354 reads of the
total 10,882 as belonging to the taxa Cripavirus. This matches the taxonomy of DCV and
suggests most of the strands sequenced were DCV virion RNA.
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APPENDICES
Appendix I: RNA isolation protocol with TRIzol®
1. HOMOGENIZATION
a. Chill fly and put it into a clean tube with 200µl of TRIzol®
i. (for multiple flies add 100µl per extra fly up to 1ml; up to 50 flies
can be done in 1 ml of TRIzol®. If doing more than one fly, ramp
all volumes accordingly (except for ethanol washes and final
suspension, those stay constant)
b. Homogenize on ice with Kontes homogenizers until only the wings and
bits of exoskeleton are distinguishable
c. Cap and vortex each tube on electric vortexer at max speed for 5 seconds
[Shake by hand it you want long RNA (>2000bp) but yield will probably
go down some]
d. Incubate the homogenized samples for 5 minutes at room temp
2. PHASE SEPARATION
a. Add 40µl of chloroform for the first fly and 20µl more for each additional
fly
b. Cap sample tubes securely
c. Vortex tubes for 5 seconds and incubate them at room temperature for 2 to
3 minutes
d. Centrifuge the sample at no more than 12,000 × g for 10 minutes at 2 to
8°C
i. Following centrifugation, the mixture separates into a lower red,
phenol-chloroform phase, an interphase that has the protein
precipitate, and a colorless upper aqueous phase. RNA remains
exclusively in the aqueous phase. The volume of the aqueous
phase is about 60% of the volume of TRIzol® Reagent used for
homogenization.
e. Transfer the aqueous phase to a fresh tube
i. Do not contaminate the aqueous phase with any of the other
phases. IF you do, you can centrifuge the samples again and try
again.
3. RNA PRECIPITATION
a. Add 100µl of isopropyl alcohol (50µl more for each additional fly) to the
aqueous phase and shake vigorously
b. Incubate samples at -20ºC for 10 minutes
c. Centrifuge at no more than 12,000 × g for 10 minutes at 2 to 8°C.
i. This should produce a gel-like whitish pellet on the side and
bottom of the tube
ii. Remove supernatant and discard
4. RNA WASH
a. Add 1 ml of cold (-4ºC) 75% ethanol (this volume remains the same
whether you do 1-10 flies)
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b. Mix the sample by vortexing and centrifuge at no more than 7,500 × g for
5 minutes at 2 to 8°C
i. RNA can be left in alcohol at 4ºC for 1 week or longer at-20ºC
c. Discard alcohol
d. Quick spin the tubes and use a pipette to discard extra alcohol at bottom of
tubes
e. Air-dry the RNA pellet for 5 minutes
5. REDISSOLVING THE RNA
a. Dissolve RNA
i. add 29µl of DEPC-treated RNase-free water
ii. add 1µl of RNAse inhibitor and mix by flicking he tube for about
10 seconds
iii. Incubate for 10 minutes at 55°C
b. Cool the tube on ICE, give a quick spine and Store at -70°C
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Appendix II: Reverse Transcription
1. PRIMER PREPARATION
a. Mix and centrifuge each component before use. Combine the following:
i. 2µl Experimental RNA (at concentration of 200ng/µl)
ii. 1µl Random Primer
iii. 2µl Nuclease-Free Water
b. Heat in a 70°C heat block for 5 minutes
i. Chill immediately in ice water for 5 minutes
ii. Centrifuge for 10 seconds in a microcentrifuge
iii. Store on ice until reverse transcription is added
2. REVERSE TRANSCRIPTION PREPARATION
a. Prepare the reverse transcription reaction mix on ice in the order listed:
i. 4µl GoScript™ 5X Reaction Buffer
ii. 2µl MgCl2 (Concentration of 2mM)
iii. 1µl PCR Nucleotide Mix (Concentration of 0.5mM each dNTP)
iv. 0.5µl Recombinant RNasin® Ribonuclease Inhibitor (20 units)
v. 0.1µl GoScript™ Reverse Transcriptase
vi. 7.4µl Nuclease-Free Water
b. Combine 15µl of reverse transcription mix with 5µl of RNA and primer
mix
3. ANNEAL AND EXTEND
a. Anneal in a heat block at 25°C for 5 minutes
b. Extend in a heat block at 42°C for 1 hour
i. Reaction can be stopped and stored at 0-5°C for analysis of cDNA
4. REVERSE TRANSCRIPTASE INACTIVATION
a. Inactivate Reverse Transcriptase before proceeding with qPCR in heat
block at 70°C for 15 minutes
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Appendix III: qPCR
1. COMPONENT PREPARATION
a. Combine the following for a 96-Well plate (15µl/well)
i. 7.5µl SYBR® Select Master Mix for CFX (2X)
ii. 1µl Forward Primer
iii. 1µl Reverse Primer
iv. 1µl cDNA Template
v. 4.5µl RNase-Free Water
b. Mix components thoroughly then centrifuge briefly to eliminate air
bubbles
2. PLATE PREPARATION
a. Transfer 15µl of reaction mix to each well of an optical plate
b. Seal the plate with an optical adhesive cover
i. centrifuge the plate to spin down content and eliminate air bubbles
c. qPCR can be performed on the reaction plate at any time up to 72 hours
when kept at room temperature and protected from exposure to direct light
3. QPCR SETTINGS
a. Run the PCR Reaction Plate with a CFX real-time PCR system using
settings of:
i. 95°C for 2 minutes
ii. 40 cycles of:
1. 94°C for 10 seconds
2. 55°C for 30 seconds
3. 72°C for 30 seconds
iii. Melting Curve
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Appendix IV: Inoculum preparation for serial passage 2 through 11
1. HOMOGENIZATION
a. Add 10 flies to a clean 1.5ml tube
i. Add 200µl of Schneider’s medium
b. Homogenize on ice with Kontes homogenizers until only the wings and
bits of exoskeleton are distinguishable
c. Cap tubes and vortex for 5 seconds
d. Centrifuge at 5°C for 5 minutes at 30,000 rcf
2. SUPERNATANT COLLECTION
a. Add supernatant to a fresh 1.5 ml tube
b. Do not contaminate with exoskeleton pellet. Store supernatant at -80°C
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Appendix V: Nanopore Sequencing
1. REVERSE TRANSCRIPTION AND STRAND-SWITCHING
a. Transfer 100 ng of prepared RNA into a 1.5 ml Eppendorf DNA LoBind
Tube
i. Adjust volume using no greater than 7.5 ul of nuclease-free water
ii. Mix by flicking tube to prevent shearing and spin down for 5
seconds in microfuge
b. Prepare the following in a separate 0.2 ml PCR tube (1) for a total volume
of 11 ul:
i. Mix gently by flicking and spin down for 5 seconds in microfuge
ii. Incubate at 65 C for 5 minutes then cool immediately on a -20 prechilled freezer block
c. In a separate 0.2 ml PCR tube (2) mix the following for a total of 8 ul:
i. Mix gently by flicking and spin down for 5 seconds in microfuge
d. Add the prepared strand-switching buffer from Step 3 to the cooled 0.2 ml
PCR tube from Step 2
i. Mix gently by flicking and spin down for 5 seconds in microfuge
ii. Incubate at 42 C for 2 minutes
e. Add 1 ul of Maxima H Minus Reverse Transcriptase so the volume is now
20 ul.
i. Mix gently by flicking and spin down for 5 seconds in microfuge
ii. Incubate on a PCR cycler using the following protocol:
2. RNA DEGRADATION AND SECOND-STRAND SYNTHESIS
a. Add 1 ul of RNase Cocktail Enzyme Mix to the prepared reverse
transcription reaction
i. Incubate for 10 minutes at 37 C
ii. During this incubation, resuspend the AMPure XP beads by
vortexing
b. Transfer the reverse transcription and RNase mix to a new 1.5 ml
Eppendorf DNA LoBind tube
c. Add 17 ul of the resuspended AMPure XP beads
i. Mix by gently flicking the tube
ii. Incubate on a Hula rotating mixer or rotating by hand for 5 minutes
at room temperature
1. During this incubation prepare 500 ul of fresh 70% ethanol
in nuclease-free water
iii. Spin down the sample for 5 seconds on a microfuge
d. Place tube on the magnet and allow a pellet to form
e. While keeping the tube on the magnet, pipette and discard supernatant
f. While still on magnet, wash the beads with 200 ul of the freshly prepared
70% ethanol without disturbing the pellet
i. Remove ethanol using a pipette and discard
ii. Repeat previous steps 3. f-i
iii. Spin down the sample for 5 seconds on a microfuge
g. Place the tube back on the magnet and allow pellet to form
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i. Pipette off any residual ethanol
ii. Allow pellet to dry for no longer than 30 seconds
h. Remove the tube from the magnetic rack and resuspend pellet in 20 ul of
nuclease-free water
i. Incubate on a Hula rotating mixer or rotating by hand for 10
minutes at room temperature
i. Place tube on the magnetic and allow pellet to form
i. Ensure the eluate is clear and colorless
j. Remove 20 ul of the supernatant and pipette into a new 1.5 ml Eppendorf
DNA LoBind tube
k. Prepare the following reaction in a 0.2 ml thin-walled PCR tube for a total
of 50 ul:
l. Incubate using the following protocol:
m. Resuspend the AMPure XP beads by vortexing
n. Transfer the sample to a clean 1.5 ml Eppendorf DNA LoBind tube
o. Add 40 ul of the resuspended AMPure XP beads, mix by gently flicking
tube
i. Incubate on a Hula rotating mixer or rotating by hand for 5 minutes
at room temperature
1. During this incubation prepare 500 ul of fresh 70% ethanol
in nuclease-free water
ii. Spin down the sample for 5 seconds in a microfuge
p. Place tube on the magnet and allow a pellet to form
i. While keeping the tube on the magnet, pipette and discard
supernatant
q. While still on magnet, wash the beads with 200 ul of the freshly prepared
70% ethanol without disturbing the pellet
i. Remove ethanol using a pipette and discard
ii. Repeat previous steps 11. q-i
iii. Spin down the sample for 5 seconds on a microfuge
r. Place the tube back on the magnet and allow a pellet to form
i. Pipette off any residual ethanol
ii. Allow pellet to dry for no longer than 30 seconds
s. Remove the tube from the magnetic rack and resuspend pellet in 21 ul of
nuclease-free water
i. Incubate on a Hula rotating mixer or rotating by hand for 10
minutes at room temperature
t. Place tube on the magnetic and allow pellet to form
i. Ensure the eluate is clear and colorless
ii. Remove 21 ul of the supernatant and pipette into a new 1.5 ml
Eppendorf DNA LoBind tube
u. Analyze 1 ul of the strand-switched DNA for size, quantity, and quality
3. END-PREP: END REPAIR AND DA-TAILING OF FRAGMENTED DNA
a. Mix the following reagents in a 0.2 ml PCR tube for a total of 60 ul:
i. Mix gently by pipetting and spin down for 5 seconds on microfuge
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ii. Incubate using a thermal cycler: 20 C for 5 minutes then 65 C for 5
minutes
1. During incubation, resuspend the AMPure XP beads by
vortexing
b. Transfer the sample to a new 1.5 ml DNA LoBind Eppendorf tube
i. Add 60 ul of the resuspended AMPure XP beads and mix gently by
pipetting
ii. Incubate on a Hula rotating mixer or rotating by hand for 5 minutes
at room temperature
1. During incubation prepare 500 ul of fresh 70% ethanol in
nuclease-free water
iii. Spin down sample for 5 seconds on microfuge
c. Place tube on the magnet and allow a pellet to form
i. While keeping the tube on the magnet, pipette and discard
supernatant
d. While still on magnet, wash the beads with 200 ul of the freshly prepared
70% ethanol without disturbing the pellet
i. Remove ethanol using a pipette and discard
ii. Repeat previous steps d-i
iii. Spin down the sample for 5 seconds on a microfuge
e. Place the tube back on the magnet and allow a pellet to form
i. Pipette off any residual ethanol
ii. Allow pellet to dry for no longer than 30 seconds
f. Remove the tube from the magnetic rack and resuspend pellet in 21 ul of
nuclease-free water
i. Incubate on a Hula rotating mixer or rotating by hand for 10
minutes at room temperature
g. Place tube on the magnetic and allow pellet to form
i. Ensure the eluate is clear and colorless
h. Remove 30 ul of the supernatant and pipette into a new 1.5 ml Eppendorf
DNA LoBind tube
4. ADAPTER LIGATION
a. Mix the contents of each tube by flicking, check there is no precipitate
present
i. Spin down sample for 5 seconds on a microfuge
b. Perform the adapter ligation process as follows for a total of 100 ul:
i. Mix by flicking the tube in between each addition
ii. Spin down for 5 seconds on microfuge
iii. Incubate the reaction for 10 minutes at room temperature
5. XP BEAD BINDING
a. Resuspend the AMPure XP beads by vortexing
i. Add 40 ul of resuspended AMPure XP beads to the adapter
ligation reaction from previous step
ii. Mix gently by pipetting
iii. Incubate on a Hula rotating mixer or rotating by hand for 5 minutes
at room temperature
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b. Place tube on the magnetic rack and allow a pellet to form
i. While keeping the tube on the magnet, pipette off and discard
supernatant
c. Remove tube from the magnetic rack
i. Add 200 ul of the Adapter Bead Binding Buffer (ABB) to the
beads
ii. Resuspend the beads by gently pipetting up and down
d. Return the tube to the magnetic rack and allow a pellet to form
i. While keeping the tube on the magnet, pipette off and discard
supernatant
ii. Repeat steps d-i
iii. Spin down the sample for 5 seconds on the microfuge
e. Place tube on the magnetic rack and allow a pellet to form
i. While keeping the tube on the magnet, pipette off and discard
supernatant
f. Remove the tube from the magnetic rack
i. Resuspend the pellet in 13 ul of Elution Buffer (EB)
ii. Incubate on a Hula rotating mixer or rotate by hand for 10 minutes
at room temperature
g. Place tube on the magnetic and allow pellet to form
i. Ensure the eluate is clear and colorless
h. Remove 13 ul of the supernatant and pipette into a new 1.5 ml Eppendorf
DNA LoBind tube
i. Quantify 1 ul of eluted cDNA using a Qubit fluorometer –
recovery aim ~60 ng
6. PRIMING AND LOADING THE SPOTON FLOW CELL
a. Before starting: thaw the Sequencing Buffer (SQB), Loading Beads (LB),
Flush Tether (FLT), and one tube of the Flush Buffer (FB)/(PFB) at room
temperature
i. Place the tubes on ice as soon as thawing is complete
ii. Mix by vortexing, spin down for 5 seconds in microfuge
iii. Store on ice
b. Open the MinION lid and slide the flow cell under the clip
i. Press down firmly to ensure complete contact is made
c. Slide the priming port cover clockwise to open the priming port
d. After opening the priming port, check for air bubbles under the cover
i. Set a P1000 pipette to 200 ul
ii. Insert pipette tip into the primer port
iii. Slowly turn the wheel until you can see a small volume of buffer
entering the pipette tip
e. Prepare the flow cell priming mix:
i. If using EXP-FLP001.PRO.6: add 46 µl of thawed and mixed
Flush Tether (FLT) directly to the tube of thawed and mixed
PromethION Flush Buffer (PFB), and mix by vortexing OR
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f.

g.
h.
i.

j.

k.

ii. If using EXP-FLP002: add 30 µl of thawed and mixed Flush
Tether (FLT) directly to the tube of thawed and mixed Flush
Buffer (FB) and mix by vortexing.
Load 800 ul of the priming mix into the flow cell via the priming port
without introducing air bubbles
i. Wait for 5 minutes (Do steps g - h at this time)
Mix the contents of the Loading Beads (LB) by pipetting (the beads settle
quickly to use immediately after mixing)
In a new 1.5 ml tube prepare the following library for a total of 75 ul:
Complete the flow cell priming:
i. Gently life the SpotON sample port cover
ii. Load 200 ul of the priming mix into the flow cell via the priming
port (Not the SpotON sample port)
Mix the prepared library from Step 8 by gently pipetting up and down
i. Add 75 ul of the sample to the flow cell via the SpotON sample
port dropwise – ensure each drop flows into the port before adding
the next
Gently replace the SpotON sample port cover
i. Ensure the bung enters the SpotON port
ii. Close the priming port and close the MinION lid
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